

MANHATTAN PHARMACEUTICALS INC  
Form 10-Q  
November 15, 2010  
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 10-Q

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2010

OR

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number 001-32639

Manhattan Pharmaceuticals, Inc.  
(Exact Name of Registrant as Specified in Its Charter)

Delaware  
(State or other jurisdiction of  
incorporation or organization)

36-3898269  
(I.R.S. Employer Identification No.)

48 Wall Street, New York, New York 10005  
(Address of principal executive offices)

(212) 582-3950  
(Issuer's telephone number)

Check whether the issuer: (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).  
Yes  No

As of November 8, 2010 there were 120,965,260 shares of the issuer's common stock, \$.001 par value, outstanding.

---

## INDEX

	Page
<b>PART I FINANCIAL INFORMATION</b>	
<b>Item 1. Financial Statements:</b>	
Unaudited Condensed Consolidated Balance Sheets	4
Unaudited Condensed Consolidated Statements of Operations	5
Unaudited Condensed Consolidated Statements of Stockholders' Equity (Deficiency)	6
Unaudited Condensed Consolidated Statements of Cash Flows	8
Notes to Unaudited Condensed Consolidated Financial Statements	10
<b>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</b>	<b>26</b>
<b>Item 3. Quantitative and Qualitative Disclosure About Market Risk</b>	<b>39</b>
<b>Item 4. Controls and Procedures</b>	<b>39</b>
<b>PART II OTHER INFORMATION</b>	
<b>Item 1. Legal Proceedings</b>	<b>40</b>
<b>Item 1A. Risk Factors</b>	<b>40</b>
<b>Item 6. Exhibits</b>	<b>40</b>
Signatures	41

Forward-Looking Statements

This quarterly report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities and Exchange Act of 1934. Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but not always, made through the use of words or phrases such as “anticipate,” “estimate,” “plan,” “project,” “expect,” “may,” “intend” and similar words or phrases. Accordingly, these statements involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed in them. These statements are therefore subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Such risks and uncertainties relate to, among other factors:

- the development of our drug candidates;
- the regulatory approval of our drug candidates;
- our use of clinical research centers and other contractors;
- our ability to find collaborative partners for research, development and commercialization of potential products;
- acceptance of our products by doctors, patients or payers;
- our ability to market any of our products;
- our history of operating losses;
- our ability to compete against other companies and research institutions;
- our ability to secure adequate protection for our intellectual property;
- our ability to attract and retain key personnel;
- availability of reimbursement for our product candidates;
- the effect of potential strategic transactions on our business;
- our ability to obtain adequate financing; and
- the volatility of our stock price.

Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

## Part I – Financial Information

## Item 1. Unaudited Condensed Consolidated Financial Statements

MANHATTAN PHARMACEUTICALS, INC. and SUBSIDIARY  
(A Development Stage Company)  
Condensed Consolidated Balance Sheets

	September 30, 2010 (unaudited)	December 31, 2009 (See Note 1)
<b>Assets</b>		
<b>Current assets:</b>		
Cash and cash equivalents	\$ 1,075,966	\$ 17,996
Debt issue costs, current portion	44,260	158,552
Other current assets	147,435	87,177
<b>Total current assets</b>	<b>1,267,661</b>	<b>263,725</b>
In-process research and development	17,742,110	-
Property and equipment, net	3,741	3,541
Debt issue costs	-	77,026
Other assets	21,370	21,370
<b>Total assets</b>	<b>\$ 19,034,882</b>	<b>\$ 365,662</b>
<b>Liabilities and Stockholders' Deficiency</b>		
<b>Current Liabilities:</b>		
Notes payable, current portion, net	\$ 2,036,645	\$ 1,274,062
Accounts payable and accrued expenses	395,817	291,175
Interest payable, current portion	415,256	182,193
Derivative liability	1,359,998	784,777
<b>Total current liabilities</b>	<b>4,207,716</b>	<b>2,532,207</b>
Notes payable, noncurrent portion, net	16,179,693	614,181
Interest payable, noncurrent portion	433,537	55,048
Exchange obligation	3,949,176	3,949,176
<b>Total liabilities</b>	<b>24,770,122</b>	<b>7,150,612</b>
<b>Commitments and contingencies</b>		
<b>Stockholders' deficiency:</b>		
Preferred stock, \$.001 par value. Authorized 1,500,000 shares; no shares issued and outstanding at September 30, 2010 and December 31, 2009	-	-
Common stock, \$.001 par value. Authorized 500,000,000 shares; 120,965,260 shares issued and outstanding at September 30, 2010 and 70,624,232 shares issued and outstanding on December 31, 2009	120,966	70,624
Contingently issuable shares	15,890	-
Additional paid-in capital	55,802,925	55,077,861
Deficit accumulated during the development stage	(61,675,021)	(61,933,435)
<b>Total stockholders' deficiency</b>	<b>(5,735,240)</b>	<b>(6,784,950)</b>

Total liabilities and stockholders' deficiency	\$ 19,034,882	\$ 365,662
--	---------------	------------

See accompanying notes to condensed consolidated financial statements.

MANHATTAN PHARMACEUTICALS, INC. and SUBSIDIARY  
(A Development Stage Company)  
Condensed Consolidated Statements of Operations  
(Unaudited)

	Three months ended September 30,		Nine months ended September 30,		Cumulative period from August 6, 2001 (inception) to September 30, 2010
	2010	2009	2010	2009	2010
Revenue	\$ -	\$ -	\$ -	\$ -	\$ -
<b>Costs and expenses:</b>					
Research and development	236,734	5,574	305,500	57,154	28,637,711
General and administrative	278,897	390,066	1,264,666	1,373,083	19,458,121
In-process research and development charge	-	-	-	-	11,887,807
Impairment of intangible assets	-	-	-	-	1,248,230
Loss on disposition of intangible assets	-	-	-	-	1,213,878
Total operating expenses	515,631	395,640	1,570,166	1,430,237	62,445,747
Operating loss	(515,631)	(395,640)	(1,570,166)	(1,430,237)	(62,445,747)
<b>Other (income) expense:</b>					
Equity in losses of Hedrin JV	-	105,362	-	337,048	750,000
Change in fair value of derivative liability	(830,165)	(157,778)	(2,696,900)	658,889	(2,266,830)
Interest and other income	(76,275)	(63,873)	(228,305)	(252,500)	(2,095,534)
Interest expense	349,562	136,738	937,555	396,698	1,578,955
Loss on early extinguishment of debt	-	-	159,070	-	159,070
Realized gain on sale of marketable equity securities	-	-	-	-	(76,032)
Total other (income) expense	(556,878)	20,449	(1,828,580)	1,140,135	(1,950,371)
Net income (loss)	41,247	(416,089)	258,414	(2,570,372)	(60,495,376)
Preferred stock dividends (including imputed amounts)	-	-	-	-	(1,179,645)
Net income (loss) applicable to common shares	\$ 41,247	\$ (416,089)	\$ 258,414	\$ (2,570,372)	\$ (61,675,021)
<b>Net income (loss) per common share:</b>					
Basic and diluted	\$ 0.00	\$ (0.01)	\$ 0.00	\$ (0.04)	

Weighted average shares of common  
stock outstanding:

Basic and diluted	120,965,244	70,624,232	108,812,838	70,624,232
-------------------	-------------	------------	-------------	------------

See accompanying notes to condensed consolidated financial statements.

5

---



MANHATTAN PHARMACEUTICALS, INC. and SUBSIDIARY  
(A Development Stage Company)  
Condensed Consolidated Statements of Stockholders' Equity (Deficiency)  
(Unaudited)

	Common stock shares	Common stock amount	Additional paid- in capital	Deficit accumulated during the development stage	Other	Total stockholders' equity (deficiency)
Stock issued at \$0.0004 per share for subscription receivable	10,167,741	\$ 10,168	\$ (6,168)	\$ -	\$ (4,000)	\$ -
Net loss	-	-	-	(56,796)	-	(56,796)
Balance at December 31, 2001	10,167,741	10,168	(6,168)	(56,796)	(4,000)	(56,796)
Proceeds from subscription receivable	-	-	-	-	4,000	4,000
Stock issued at \$0.0004 per share for license rights	2,541,935	2,542	(1,542)	-	-	1,000
Stock options issued for consulting services	-	-	60,589	-	(60,589)	-
Amortization of unearned consulting services	-	-	-	-	22,721	22,721
Common stock issued at \$0.63 per share, net of expenses	3,043,332	3,043	1,701,275	-	-	1,704,318
Net loss	-	-	-	(1,037,320)	-	(1,037,320)
Balance at December 31, 2002	15,753,008	15,753	1,754,154	(1,094,116)	(37,868)	637,923
Common stock issued at \$0.63 per share, net of expenses	1,321,806	1,322	742,369	-	-	743,691
Effect of reverse acquisition	6,287,582	6,287	2,329,954	-	-	2,336,241
Amortization of unearned consulting costs	-	-	-	-	37,868	37,868
Unrealized loss on short-term investments	-	-	-	-	(7,760)	(7,760)
Payment for fractional shares for stock combination	-	-	(300)	-	-	(300)
Preferred stock issued at \$10 per share, net of expenses	-	-	9,045,176	-	1,000	9,046,176

Edgar Filing: MANHATTAN PHARMACEUTICALS INC - Form 10-Q

Imputed preferred stock dividend			418,182	(418,182)		-
Net loss	-	-	-	(5,960,907)		(5,960,907)
Balance at December 31, 2003	23,362,396	23,362	14,289,535	(7,473,205)	(6,760)	6,832,932
Exercise of stock options	27,600	27	30,073	-		30,100
Common stock issued at \$1.10, net of expenses	3,368,952	3,369	3,358,349	-		3,361,718
Preferred stock dividend accrued	-	-	-	(585,799)		(585,799)
Preferred stock dividends paid by issuance of shares	-	-	281,073	-	25	281,098
Conversion of preferred stock to common stock at \$1.10 per share	1,550,239	1,551	(1,380)	-	(171)	-
Warrants issued for consulting services	-	-	125,558	-	(120,968)	4,590
Amortization of unearned consulting costs	-	-	-	-	100,800	100,800
Unrealized gain on short-term investments and reversal of unrealized loss on short-term investments	-	-	-	-	20,997	20,997
Net loss	-	-	-	(5,896,031)	-	(5,896,031)
Balance at December 31, 2004	28,309,187	28,309	18,083,208	(13,955,035)	(6,077)	4,150,405
Common stock issued at \$1.11 and \$1.15, net of expenses	11,917,680	11,918	12,238,291	-		12,250,209
Common stock issued to vendor at \$1.11 per share in satisfaction of accounts payable	675,675	676	749,324	-		750,000
Exercise of stock options	32,400	33	32,367	-		32,400
Exercise of warrants	279,845	279	68,212	-		68,491
Preferred stock dividend accrued	-	-	-	(175,663)		(175,663)
Preferred stock dividends paid by issuance of shares	-	-	477,736	-	42	477,778
Conversion of preferred stock to common stock at \$1.10 per share	8,146,858	8,147	(7,251)	-	(896)	-

Edgar Filing: MANHATTAN PHARMACEUTICALS INC - Form 10-Q

Share-based compensation	-	-	66,971	-	20,168	87,139
Reversal of unrealized gain on short-term investments	-	-	-	-	(12,250)	(12,250)
Stock issued in connection with acquisition of Tarpan Therapeutics, Inc.	10,731,052	10,731	11,042,253	-	-	11,052,984
Net loss	-	-	-	(19,140,997)	-	(19,140,997)
Balance at December 31, 2005	60,092,697	60,093	42,751,111	(33,271,695)	987	9,540,496
Cashless exercise of warrants	27,341	27	(27)	-	-	-
Share-based compensation	-	-	1,675,499	-	-	1,675,499
Unrealized loss on short-term investments	-	-	-	-	(987)	(987)
Costs associated with private placement	-	-	(15,257)	-	-	(15,257)
Net loss	-	-	-	(9,695,123)	-	(9,695,123)
Balance at December 31, 2006	60,120,038	60,120	44,411,326	(42,966,818)	-	1,504,628

MANHATTAN PHARMACEUTICALS, INC. and SUBSIDIARY  
(A Development Stage Company)  
Condensed Consolidated Statements of Stockholders' Equity (Deficiency)  
(Unaudited)

	Common stock shares	Common stock amount	Additional paid-in capital	Deficit accumulated during the development stage	Other	Total stockholders' equity (deficiency)
Common stock issued at \$0.84 and \$0.90 per shares, net of expenses	10,185,502	\$ 10,186	\$ 7,841,999	\$ -	\$ -	\$ 7,852,185
Common stock issued directors at \$0.72 per share in satisfaction of accounts payable	27,776	28	19,972	-	-	20,000
Common stock issued in connection with in-licensing agreement at \$0.90 per share	125,000	125	112,375	-	-	112,500
Common stock issued to in connection with in-licensing agreement at \$0.80 per share	150,000	150	119,850	-	-	120,000
Exercise of warrants	10,327	15	7,219	-	-	7,234
Cashless exercise of warrants	5,589	-	(6)	-	-	(6)
Share-based compensation	-	-	1,440,956	-	-	1,440,956
Warrants issued for consulting	-	-	83,670	-	-	83,670
Net loss	-	-	-	(12,032,252)	-	(12,032,252)
Balance at December 31, 2007	70,624,232	70,624	54,037,361	(54,999,070)	-	(891,085)
Sale of warrant	-	-	150,000	-	-	150,000
Share-based compensation	-	-	463,890	-	-	463,890
Warrants issued with secured 12% notes	-	-	170,128	-	-	170,128
Net loss	-	-	-	(4,268,858)	-	(4,268,858)
Balance at December 31, 2008	70,624,232	70,624	54,821,379	(59,267,928)	-	(4,375,925)
Cumulative effect of a change in accounting principle	-	-	(150,000)	127,778	-	(22,222)
Balance at January 1, 2009, as adjusted	70,624,232	70,624	54,671,379	(59,140,150)	-	(4,398,147)
	-	-	353,438	-	-	353,438

Share-based compensation							
Warrants issued with secured 12% notes	-	-	46,125	-	-	-	46,125
Warrant issued to placement agent - secured 12% notes	-	-	6,919	-	-	-	6,919
Net loss	-	-	-	(2,793,285)	-	-	(2,793,285)
Balance at December 31, 2009	70,624,232	70,624	55,077,861	(61,933,435)	-	-	(6,784,950)
Common stock issued at \$0.07, net of expenses	43,278,605	43,279	2,542,207	-	-	-	2,585,486
Shares issued and issuable in Merger	7,062,423	7,063	1,468,984	-	15,890	-	1,491,937
Derivative liability associated with issuance of common stock at \$0.07	-	-	(3,497,898)	-	-	-	(3,497,898)
Share-based compensation	-	-	211,771	-	-	-	211,771
Net income	-	-	-	258,414	-	-	258,414
Balance at September 30, 2010	120,965,260	\$ 120,966	\$ 55,802,925	\$ (61,675,021)	\$ 15,890	\$	(5,735,240)

See accompanying notes to condensed consolidated financial statements.

MANHATTAN PHARMACEUTICALS, INC. and SUBSIDIARY  
(A Development Stage Company)  
Condensed Consolidated Statements of Cash Flows  
(Unaudited)

	Nine months ended September 30,		Cumulative period from August 6, 2001 (inception) to September 30, 2010
	2010	2009	
<b>Cash flows from operating activities:</b>			
Net income/(loss)	\$ 258,414	\$ (2,570,372)	\$ (60,495,376)
<b>Adjustments to reconcile net income/(loss) to net cash used in operating activities:</b>			
Equity in losses of Hedrin JV	-	337,048	750,000
Share-based compensation	211,771	271,075	4,394,082
Amortization of OID and issue costs on Secured 12% Notes	288,772	380,261	872,745
Change in fair value of derivative liability	(2,696,900)	658,889	(2,266,830)
Loss on early extinguishment of debt	159,070	-	159,070
Shares issued in connection with in-licensing agreement	-	-	232,500
Amortization of intangible assets	-	-	145,162
Depreciation	2,644	4,297	230,106
Noncash portion of in-process research and development charge	-	-	11,721,623
Loss on impairment and disposition of intangible assets	-	-	2,462,108
Other	-	-	31,555
<b>Changes in operating assets and liabilities, net of acquisitions:</b>			
Decrease in restricted cash	-	730,499	-
Decrease/(increase) in prepaid expenses and other current assets	60,612	(48,891)	31,678
Decrease/(increase) in other assets	-	13,525	(36,370)
Increase/(decrease) in accounts payable and accrued expenses	(332,972)	(498,983)	49,994
Increase in interest payable, current portion	233,063	-	233,063
Increase in interest payable, noncurrent portion	387,156	-	387,156
Net cash used in operating activities	(1,428,370)	(722,652)	(41,097,734)
<b>Cash flows from investing activities:</b>			
Purchase of property and equipment	(2,844)	-	(242,452)
Cash acquired in connection with acquisitions	519,365	-	493,334
Net cash provided from the purchase and sale of short-term investments	-	-	435,938
Proceeds from sale of license	-	-	200,001
Net cash provided by investing activities	516,521	-	886,821
<b>Cash flows from financing activities:</b>			
Proceeds from the Hedrin JV agreement	-	500,000	3,199,176
Proceeds from sale of notes payable	-	340,270	1,345,413
Repayments of notes payable	(193,667)	(70,000)	(887,067)

Edgar Filing: MANHATTAN PHARMACEUTICALS INC - Form 10-Q

Proceeds related to sale of common stock, net	2,163,486	-	28,059,748
Proceeds from sale of preferred stock, net	-	-	9,046,176
Proceeds from exercise of warrants and stock options and sale of warrant	-	-	288,219
Other, net	-	-	235,214
Net cash provided by financing activities	1,969,819	770,270	41,286,879
Net increase in cash and cash equivalents	1,057,970	47,618	1,075,966
Cash and cash equivalents at beginning of period	17,996	106,023	-
Cash and cash equivalents at end of period	\$ 1,075,966	\$ 153,641	\$ 1,075,966

See accompanying notes to condensed consolidated financial statements.

MANHATTAN PHARMACEUTICALS, INC. and SUBSIDIARY  
(A Development Stage Company)  
Condensed Consolidated Statements of Cash Flows  
(Unaudited)

	Nine months ended September 30,		Cumulative period from August 6, 2001 (inception) to September 30, 2010
	2010	2009	
<b>Supplemental disclosure of cash flow information:</b>			
Interest paid	\$ 28,212	\$ -	\$ 59,642
<b>Supplemental disclosure of noncash investing and financing activities:</b>			
Issuance of common stock for acquisitions	\$ 1,491,937	\$ -	\$ 14,881,163
Conversion of debt to common stock and warrants	422,000	-	422,000
Investment in Hedrin JV	500,000	500,000	750,000
Warrants issued with notes payable	-	53,044	250,562
Note issued to settle accrued expenses	-	-	211,900
Common stock issued in satisfaction of accounts payable	-	-	770,000
Imputed and accrued preferred stock dividend	-	-	1,179,644
Conversion of preferred stock to common stock	-	-	1,067
Preferred stock dividends paid by issuance of shares	-	-	759,134
Issuance of common stock in connection with in-licensing agreement	-	-	232,500
Marketable equity securities received in connection with sale of license	-	-	359,907
Warrants issued to consultant	-	-	83,670
Net liabilities assumed over assets acquired in business combination	-	-	(675,416)
Cashless exercise of warrants	-	-	33

See accompanying notes to condensed consolidated financial statements



MANHATTAN PHARMACEUTICALS, INC. and SUBSIDIARY  
(a Development Stage Company)  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of Manhattan Pharmaceuticals, Inc. ("Manhattan") and subsidiaries (the "Company") have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the rules and regulations of the Securities and Exchange Commission. Accordingly, the unaudited condensed consolidated financial statements do not include all information and footnotes required by accounting principles generally accepted in the United States of America for complete annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of only normal recurring adjustments, considered necessary for a fair presentation. Interim operating results are not necessarily indicative of results that may be expected for the year ending December 31, 2010 or for any other interim period. These unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited financial statements as of and for the year ended December 31, 2009, which are included in the Company's Annual Report on Form 10-K for such year. The condensed balance sheet as of December 31, 2009 has been derived from the audited financial statements included in the Form 10-K for that year.

As of September 30, 2010, the Company has not generated any revenues from the development of its products and is therefore still considered to be a development stage company.

On March 8, 2010, Manhattan entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Company, Ariston Pharmaceuticals, Inc., a Delaware corporation ("Ariston") and Ariston Merger Corp., a Delaware corporation and wholly-owned subsidiary of the Company (the "Merger Sub"). Pursuant to the terms and conditions set forth in the Merger Agreement, on March 8, 2010, the Merger Sub merged with and into Ariston (the "Merger"), with Ariston being the surviving corporation of the Merger. As a result of the Merger, Ariston became a wholly-owned subsidiary of Manhattan. The operating results of Ariston from March 8, 2010 to September 30, 2010 are included in the accompanying condensed consolidated statements of operations. The condensed consolidated balance sheet as of September 30, 2010 reflects the acquisition of Ariston, effective March 8, 2010, the date of the Merger.

Segment Reporting

The Company has determined that it operates in only one segment currently, which is biopharmaceutical research and development.

Financial Instruments

At September 30, 2010 and December 31, 2009, the fair values of cash and cash equivalents, accounts payable, the convertible 5% notes payable, the ICON convertible note payable and the secured 12% notes payable approximate their carrying values. At December 31, 2009 the fair value of the convertible 12% note does not approximate its carrying value as a portion of the fair value is reflected as a component of derivative liability. On April 8, 2010, the holder of the convertible 12% note exercised its option to convert (see Note 6).

Equity in Joint Venture

The Company accounts for its investment in joint venture (see Note 5) using the equity method of accounting. Under the equity method, the Company records its pro-rata share of joint venture income or losses and adjusts the basis of its investment accordingly.

MANHATTAN PHARMACEUTICALS, INC. and SUBSIDIARY  
(a Development Stage Company)  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

New Accounting Pronouncements

In January 2010, the Financial Accounting Standards Board (“FASB”) issued a new pronouncement, Improving Disclosures about Fair Value Measurements. This provision amends previous provisions that require reporting entities to make new disclosures about recurring and nonrecurring fair value measurements including the amounts of and reasons for significant transfers into and out of Level 1 and Level 2 fair value measurements and separate disclosure of purchases, sales, issuances, and settlements in the reconciliation of Level 3 fair value measurements. This pronouncement was effective for interim and annual reporting periods beginning after December 15, 2009, except for Level 3 reconciliation disclosures which are effective for interim and annual periods beginning after December 15, 2010. The adoption of this pronouncement did not have a material impact on the Company’s results of operations or financial condition.

In April 2010, the FASB issued a new pronouncement “Revenue Recognition – Milestone Method”. This pronouncement provides guidance on the criteria that should be met for determining whether the milestone method of revenue recognition is appropriate. A vendor can recognize consideration that is contingent upon achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone meets all criteria to be considered substantive. The following criteria must be met for a milestone to be considered substantive. The consideration earned by achieving the milestone should 1. Be commensurate with either the level of effort required to achieve the milestone or the enhancement of the value of the item delivered as a result of a specific outcome resulting from the vendor’s performance to achieve the milestone. 2, Related solely to past performance. 3. Be reasonable relative to all deliverables and payment terms in the arrangement. No bifurcation of an individual milestone is allowed and there can be more than one milestone in an arrangement. Accordingly, an arrangement may contain both substantive and nonsubstantive milestones. This pronouncement is effective on a prospective basis for milestones achieved in fiscal years, and interim periods within those years, beginning on or after June 15, 2010. The adoption of this guidance does not have a material impact on our financial statements.

Ariston Merger

On March 8, 2010, Manhattan entered into the Merger Agreement by and among the Company, Ariston and Merger Sub. Pursuant to the terms and conditions set forth in the Merger Agreement, on March 8, 2010, the Merger Sub merged with and into Ariston, with Ariston being the surviving corporation of the Merger. As a result of the Merger, Ariston became a wholly-owned subsidiary of the Manhattan.

Under the terms of the Merger Agreement, the consideration payable by Manhattan to the stockholders and note holders of Ariston consists of the issuance of 7,062,423 shares of Manhattan’s common stock, par value \$0.001 per share, (“Common Stock”) at Closing (as defined in the Merger Agreement) plus the right to receive up to an additional 24,718,481 shares of Common Stock (the “Milestone Shares”) upon the achievement of certain product-related milestones described below. In addition, the Manhattan has reserved 38,630,723 shares of its Common Stock for possible future issuance in connection with the conversion of \$15.45 million of outstanding Ariston convertible promissory notes. The noteholders will not have any recourse to Manhattan for repayment of the notes (their sole recourse being to Ariston), but the noteholders will have the right to convert the notes into shares of the Manhattan’s Common Stock at the rate of \$0.40 per share. Further, Manhattan has reserved 5,000,000 shares of its Common Stock for possible future issuance in connection with the conversion of the \$1.0 million outstanding Ariston convertible promissory note issued in satisfaction of a trade payable. The noteholder will not have any recourse to Manhattan for repayment of the note (their sole recourse being to Ariston), but the noteholder will have the right to

convert the note into shares of Manhattan's Common Stock at the rate of \$0.20 per share.

Upon the achievement of the milestones described below, Manhattan would be obligated to issue portions of the Milestone Shares to the former Ariston stockholders and noteholders:

- Upon the affirmative decision of Manhattan's Board of Directors, provided that such decision is made prior to March 8, 2011, to further develop the AST-915, either internally or through a corporate partnership, Manhattan would issue 8,828,029 of the Milestone Shares.
- Upon the acceptance by the FDA of the Ariston's filing of the first New Drug Application for the AST-726 product candidate, Manhattan would issue 7,062,423 of the Milestone Shares.
- Upon the Company receiving FDA approval to market the AST-726 product candidate in the United States of America, Manhattan would issue 8,828,029 of the Milestone Shares.

MANHATTAN PHARMACEUTICALS, INC. and SUBSIDIARY  
(a Development Stage Company)  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Certain members and former members of Manhattan's board of directors and principal stockholders of Manhattan owned Ariston securities. Timothy McInerney, a director of Manhattan, owned 16,668 shares of Ariston common stock which represented less than 1% of Ariston's outstanding common stock as of the closing of the Merger. Neil Herskowitz, a director of Manhattan, indirectly owned convertible promissory notes of Ariston with interest and principal in the amount of \$192,739. Michael Weiser, a director of Manhattan, owned 117,342 shares of Ariston common stock, which represented approximately 2.1% of Ariston's outstanding common stock as of the closing of the Merger. Lindsay Rosenwald, a more than 5% beneficial owner of Manhattan common stock, in his individual capacity and indirectly through trusts and companies he controls or owned 497,911 shares of Ariston common stock, which represented approximately 8.9% of Ariston's outstanding common stock as of the closing of the Merger and indirectly owned convertible promissory notes of Ariston in the amount of \$141,438.

The Company merged with Ariston principally to add new products to our portfolio. Prior to the Merger, Ariston was a private, clinical stage specialty biopharmaceutical company based in Shrewsbury, Massachusetts that in-licensed, developed and planned to market novel therapeutics for the treatment of serious disorders of the central and peripheral nervous systems.

The Merger date fair value of the total consideration paid was \$1,491,937 which consisted of 7,062,423 shares of the Company's common stock issued upon the Merger and 15,890,452 contingently issuable shares upon Ariston's attaining certain milestones as described above. At the time of the Merger, the Company did not believe the attainment of the milestone for AST-915 was highly probable and, therefore, recorded no contingent consideration relative to it. The par value of the contingently issuable common shares is reflected in the accompanying condensed consolidated balance sheets as of September 30, 2010 as a component of stockholders' deficiency, contingently issuable shares.

The following table summarizes the fair values of the assets acquired and liabilities assumed at the Merger date:

Cash and cash equivalents	\$ 519,365
Other assets	120,870
Total identifiable assets	640,235
Accounts payable and accrued expenses	437,615
ICON convertible note payable	1,000,000
5% convertible notes payable	15,452,793
Total identifiable liabilities	16,890,408
Net identifiable assets (liabilities)	(16,250,173)
In-process research and development acquired	17,742,110
Net assets acquired	\$ 1,491,937

MANHATTAN PHARMACEUTICALS, INC. and SUBSIDIARY  
(a Development Stage Company)  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The following supplemental pro forma information presents the financial results as if the acquisition of Ariston had occurred on January 1, 2009 for the quarter ended September 30, 2009 and nine month period ended September 30, 2009 and on January 1, 2010 for the quarter ended September 30, 2010 and the nine month period ended September 30, 2010. This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2009 or January 1, 2010, nor are they indicative of future results.

Pro forma consolidated results:

	Quarter ended September 30,		Nine months ended September	
	2010	2009	2010	2009
Revenue	\$ -	\$ -	\$ -	\$ -
Net income(loss)	\$ 41,247	\$ (731,126)	\$ 104,411	\$ (4,328,629)
Basic and diluted earnings(loss) per share	\$ 0.01	\$ (0.01)	\$ 0.00	\$ (0.06)

## 2. LIQUIDITY

The Company had a net income of \$258,414 and negative cash flows from operating activities of \$1,428,370 for the nine month period ended September 30, 2010. The net loss applicable to common shares from date of inception, August 6, 2001, to September 30, 2010 amounts to \$61,675,021.

During the nine months ended September 30, 2009 the Company received approximately \$0.3 million from the final closing of the sale of Secured 12% Notes and approximately \$0.5 million from a joint venture agreement.

During the nine months ended September 30, 2010, the Company received \$40,000 from Ariston Pharmaceuticals, Inc. in exchange for notes in January 2010 and approximately \$2.2 million from an equity financing transaction (see Note 7). In addition approximately \$422,000 of notes payable and interest payable thereon was converted in this equity financing transaction. The Company repaid the \$40,000 received from Ariston in the first quarter of 2010 and the \$27,000 received from Ariston in the fourth quarter of 2009 together with interest thereon prior to the Merger.

Management believes that the Company will continue to incur net losses through at least September 30, 2011 and for the foreseeable future. Based on the resources of the Company available at September 30, 2010, management believes that the Company has sufficient capital to fund its operations through the end of 2010. Management believes that the Company will need additional equity or debt financing or will need to generate positive cash flow from a joint venture agreement, see Note 5, or generate revenues through licensing of its products or entering into strategic alliances to be able to sustain its operations into 2011. Furthermore, the Company will need additional financing thereafter to complete development and commercialization of our products. There can be no assurances that we can successfully complete development and commercialization of our products. In addition, \$1,725,000 principal amount of debt plus interest thereon matures in three tranches beginning in November 2010. The Company does not have the funds to repay this debt and is negotiating with representatives of the debt holders for either an extension of the maturity date or a conversion into of the debt into equity. If the Company cannot reach agreement with the debt holders the Company will be in default on the debt.

In November 2010 \$1,316,000 of principal and interest matures, in December 2010 \$356,000 of interest and principal matures and in February 2011 \$521,000 of principal and interest matures. If the Company defaults on these debt obligations the debtholders have the right to appoint a collateral agent and have that collateral agent foreclose on the collateral. The collateral is principally comprised of Manhattan's investment in Ariston and the Company's interest in the Hedrin JV. Foreclosure on the collateral would render the Company bankrupt. If the Company cannot reach agreement with the debtholders the Company may have to file for voluntary bankruptcy.

The Company does not have the financial resources necessary to conduct the pivotal trial of AST-726 and will have to raise funds for that purpose.

The Company's continued operation will depend on its ability to raise additional funds through various potential sources such as equity and debt financing, collaborative agreements, strategic alliances and its ability to realize the full potential of its technology in development. Additional funds may not become available on acceptable terms, and there can be no assurance that any additional funding that the Company does obtain will be sufficient to meet the Company's needs in the long-term.

These matters raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

MANHATTAN PHARMACEUTICALS, INC. and SUBSIDIARY  
(a Development Stage Company)  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

3. COMPUTATION OF NET INCOME (LOSS) PER COMMON SHARE

Basic net income (loss) per common share is calculated by dividing net income (loss) applicable to common shares by the weighted-average number of common shares outstanding for the period. Diluted net income (loss) per common share is the same as basic net income (loss) per common share for the three and nine months ended September 30, 2009, since potentially dilutive securities from stock options and stock warrants would have an antidilutive effect because the Company incurred a net loss during each of those periods. The amounts of potentially dilutive securities excluded from the calculation were 211,559,852 and 99,159,628 shares at September 30, 2010 and 2009, respectively. These amounts do not include the 71,428,571 shares issuable upon the exercise of the put or call rights issued in connection with the Hedrin JV (see Note 5) which were subject to anti-dilution rights upon the issuance of common shares in the 2010 equity financing transaction (see Note 7). At September 30, 2010, all of the dilutive securities are out of the money and are, therefore, excluded from the computation of diluted earnings per share for the three and nine month periods ended September 30, 2010.

4. SHARE-BASED COMPENSATION

The Company has stockholder-approved stock incentive plans for employees, directors, officers and consultants. Prior to January 1, 2006, the Company accounted for the employee, director and officer plans using the intrinsic value method. On January 1, 2006, the Company adopted the share-based payment method for employee options using the modified prospective transition method. Under the modified prospective transition method, the Company recognized compensation cost for the quarters ended September 30, 2010 and 2009 which includes: a) period compensation cost related to share-based payments granted prior to, but not yet vested, as of January 1, 2006, based on the grant date fair value estimated in accordance with the original provisions; and b) period compensation cost related to share-based payments granted on or after January 1, 2006, based on the grant date fair value estimated in accordance with the accounting methodology.

The Company recognizes compensation expense related to stock option grants on a straight-line basis over the vesting period. The Company recognized share-based compensation cost of \$5,630 and \$78,605 for the three month periods ended September 30, 2010 and 2009 respectively, and \$211,771 and \$271,075 for the nine month periods ended September 30, 2010 and 2009, respectively. The Company did not capitalize any share-based compensation cost.



MANHATTAN PHARMACEUTICALS, INC. and SUBSIDIARY  
(a Development Stage Company)  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Options granted to consultants and other non-employees are recorded at fair value at the date of grant and subsequently adjusted to fair value at the end of each reporting period until such options vest, and the fair value of the options, as adjusted, is amortized to consulting expense over the related vesting period. Accordingly, such options are recorded at fair value at the date of grant and subsequently adjusted to fair value at the end of each reporting period until such options vest, and the fair value of the options, as adjusted, is amortized to consulting expense over the related vesting period. As a result of adjusting consultant and other non-employee options to fair value, the Company recognized share-based compensation cost of \$33 and \$107, respectively, for the three-and nine months ended September 30, 2010 and \$382 and \$1,151, respectively, for the three-and nine months ended September 30, 2009. The Company has allocated share-based compensation costs to general and administrative and research and development expenses as follows:

	Three months ended September 30,		Nine months ended September 30,	
	2010	2009	2010	2009
<b>General and administrative expense:</b>				
Share-based employee compensation cost	\$ 5,597	\$ 78,223	\$ 211,664	\$ 269,924
Share-based consultant and non-employee cost	3	38	11	115
	5,600	78,261	211,675	270,039
<b>Research and development expense:</b>				
Share-based employee compensation cost	-	-	-	-
Share-based consultant and non-employee cost	30	344	96	1,036
	30	344	96	1,036
<b>Total share-based cost</b>	<b>\$ 5,630</b>	<b>\$ 78,605</b>	<b>\$ 211,771</b>	<b>\$ 271,075</b>

To compute compensation charges in 2010 and 2009 the Company estimated the fair value of each option award on the date of grant using the Black-Scholes model. The Company based the expected volatility assumption on a volatility index of peer companies as the Company did not have a sufficient number of years of historical volatility of its common stock. The expected term of options granted represents the period of time that options are expected to be outstanding. The Company estimated the expected term of stock options by the simplified method. The expected forfeiture rates are based on the historical employee forfeiture experiences. To determine the risk-free interest rate, the Company utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected term of the Company's awards. The Company has not declared a dividend on its common stock since its inception and has no intentions of declaring a dividend in the foreseeable future and therefore used a dividend yield of zero.

The following table shows the weighted average assumptions the Company used to develop the fair value estimates for the determination of the compensation charges in 2010 and 2009:

	Nine months ended September 30,	
	2010	2009
Expected volatility	88%	94%

Edgar Filing: MANHATTAN PHARMACEUTICALS INC - Form 10-Q

Dividend yield	-	-
Expected term (in years)	5.7	6
Risk-free interest rate	2.46%	2.08%

MANHATTAN PHARMACEUTICALS, INC. and SUBSIDIARY  
(a Development Stage Company)  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The Company has shareholder-approved incentive stock option plans for employees under which it has granted non-qualified and incentive stock options. In December 2003, the Company established the 2003 Stock Option Plan (the "2003 Plan"), which provided for the granting of up to 5,400,000 options to officers, directors, employees and consultants for the purchase of stock. In August 2005, the Company increased the number of shares of common stock reserved for issuance under the 2003 Plan by 2,000,000 shares. In May 2007, the Company increased the number of shares of common stock reserved for issuance under the 2003 Plan by 3,000,000 shares. In November 2009, the Company increased the number of shares of common stock reserved for issuance under the 2003 plan by an additional 4,600,000 shares. At September 30, 2010, 15,000,000 shares were authorized for issuance. The options have a maximum term of 10 years and vest over a period determined by the Company's Board of Directors (generally 3 years) and are issued at an exercise price equal to or greater than the fair market value of the shares at the date of grant. The 2003 Plan expires on December 10, 2013 or when all options have been granted, whichever is sooner. At September 30, 2010 options to purchase 11,574,936 shares were outstanding, 27,776 shares of common stock were issued and there were 4,524,528 shares reserved for future grants under the 2003 Plan.

In July 1995, the Company established the 1995 Stock Option Plan (the "1995 Plan"), which provided for the granting of options to purchase up to 130,000 shares of the Company's common stock to officers, directors, employees and consultants. The 1995 Plan was amended several times to increase the number of shares reserved for stock option grants. In June 2005 the 1995 Plan expired and no further options can be granted. At September 30, 2010 options to purchase 1,127,240 shares were outstanding and no shares were reserved for future stock option grants under the 1995 Plan.

A summary of the status of the Company's stock options as of September 30, 2010 and changes during the period then ended is presented below:

	Shares	Weighted average exercise price	Weighted Average Remaining Contractual Term (years)	Aggregate Intrinsic Value
Outstanding at December 31, 2009	7,459,936	\$ 0.718	6.160	
Granted	4,125,000	\$ 0.070	5.697	
Exercised	-			
Cancelled	(10,000)	\$ 0.280		
Outstanding at September 30, 2010	11,574,936	\$ 0.487	7.220	\$ -
Exercisable at September 30, 2010	9,983,269	\$ 0.554	6.870	\$ -
Weighted-average fair value of options granted during the nine month period ended September 30, 2010	\$ 0.046			

As of September 30, 2010, the total compensation cost related to nonvested option awards not yet recognized is \$61,919. The weighted average period over which it is expected to be recognized is approximately 2.42 years.



MANHATTAN PHARMACEUTICALS, INC. and SUBSIDIARY  
(a Development Stage Company)  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

5. JOINT VENTURE

In February 2008, the Company and Nordic Biotech Advisors ApS through its investment fund Nordic Biotech Venture Fund II K/S ("Nordic") entered into a joint venture agreement (the "Hedrin JV Agreement") to develop and commercialize the Company's North American rights (under license) to its Hedrin product.

Pursuant to the Hedrin JV Agreement, Nordic formed a new Danish limited partnership, H Pharmaceuticals K/S, (the "Hedrin JV") and provided it with initial funding of \$2.5 million and the Company assigned and transferred its North American rights in Hedrin to the Hedrin JV in return for a \$2.0 million cash payment from the Hedrin JV and equity in the Hedrin JV representing 50% of the nominal equity interests in the Hedrin JV. At closing the Company recognized an investment in the Hedrin JV of \$250,000 and an exchange obligation of \$2,054,630. The exchange obligation represents the Company's obligation to Nordic to issue the Company's common stock in exchange for all or a portion of Nordic's equity interest in the Hedrin JV upon the exercise by Nordic of the put issued to Nordic in the Hedrin JV Agreement transaction. The put is described below.

In June 2008, Nordic invested an additional \$1.0 million, for a total of \$3.5 million, in the Hedrin JV and made an advance of \$250,000 to the Hedrin JV and the Hedrin JV made an additional \$1.0 million payment, for a total of \$3.0 million, to the Company. The Hedrin JV also distributed additional ownership equity sufficient for each of the Company and Nordic to maintain their ownership interest at 50%. The FDA classified Hedrin as a Class III medical device in February 2009. Upon attaining this classification of Hedrin by the FDA, Nordic invested an additional \$1.25 million, for a total investment of \$5 million, into the Hedrin JV, the Hedrin JV paid an additional \$0.5 million, for a total of \$3.5 million, to the Company and the \$250,000 that Nordic advanced to the Hedrin JV in June became an equity investment in the Hedrin JV by Nordic.

In February 2009, the Company's exchange obligation increased by \$1,000,000 and the Company's investment in the Hedrin JV increased by \$500,000 as a result of the investment by Nordic of an additional \$1.25 million into the Hedrin JV, the reclassification of the advance made by Nordic in June 2008 to the Hedrin JV of \$250,000 into an equity interest and the payment of \$500,000 by the Hedrin JV to the Company. At September 30, 2010, the Company's exchange obligation is \$3,949,176.

During the nine months ended September 30, 2010 and 2009, the Company recognized \$0 and \$337,048, respectively, of equity in the losses of the Hedrin JV. This reduced the carrying value of its investment in the Hedrin JV to \$0 at September 30, 2010 and \$268,314 at September 30, 2009. As of September 30, 2010, the Company's estimated share of the losses is \$985,000; equity in losses previously recognized was \$500,000 leaving an estimated balance of \$485,000 of losses that were not recognized as of September 30, 2010, since the investment was already written down to zero.

The Hedrin JV is responsible for the development and commercialization of Hedrin for the North American market and all associated costs including clinical trials, if required, regulatory costs, patent costs, and future milestone payments owed to T&R, the licensor of Hedrin.

The Hedrin JV has engaged the Company to provide management services to the Limited Partnership in exchange for a management fee. For the nine months ended September 30, 2010 and 2009, the Company has recognized \$225,000 and \$258,845, respectively, of other income from management fees earned from the Hedrin JV which is included in the Company's statements of operations for the nine months ended September 30, 2010 and 2009 as a component of

interest and other income.

17

---

MANHATTAN PHARMACEUTICALS, INC. and SUBSIDIARY  
(a Development Stage Company)  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As per the Limited Partnership Agreement between the Company and Nordic (the “LPA”) in the event that a limited partner in the Hedrin JV (a “Limited Partner”) determines, in its reasonable good faith discretion, that the Hedrin JV requires additional capital for the proper conduct of its business that Limited Partner shall provide each Limited Partner with a written request for contribution of such Limited Partner’s proportionate share, in accordance with the then respective equity ownership in the Hedrin JV, of such requested additional capital amount.

As per the terms of the LPA, if a Limited Partner declines to so contribute, elects to contribute but thereafter fails to do so timely, or elects to contribute and timely does contribute some, but not all of, its proportionate share of the requested additional capital amount, the other Limited Partner shall have the option to contribute the remaining balance of such requested additional capital amount.

As per the terms of the LPA, the General Partner shall determine the fair market value of the shares for purposes of determining how to allocate the number of shares of the Hedrin JV to be issued in consideration for the contribution of capital. If the General Partner is unable to determine the fair market value of the shares, the fair market value for the shares shall be determined in good faith by the contributing Limited Partner if such amount is equal to or greater than the most recent valuation of such Hedrin JV shares.

On December 31, 2009, Nordic Biotech Venture Fund II (“Nordic”) delivered a written notice to the Company for a \$1,000,000 capital increase to the Hedrin JV. In January 2010, Nordic made its capital contribution to the Hedrin JV of \$500,000. The Company did not have sufficient funds to make such a capital contribution within the required time prescribed in the LPA.

The General Partner was unable to determine the fair market value of the shares. The contributing Limited Partner, Nordic, determined in good faith that the fair market value of the shares is equal to the most recent valuation. The most recent valuation was the February 2009 investment of \$1,500,000 into the Hedrin JV by Nordic at \$5,000 per share. As a result of Nordic’s investing an additional \$500,000 in the Hedrin JV the ownership percentages of the Hedrin JV have changed from 50% to Nordic and 50% for the Company to 52.38% to Nordic and 47.62% for the Company. In the event that Nordic exercises its option to invest the remaining \$500,000 of the \$1,000,000 capital increase then the ownership percentage shall change to 54.55% for Nordic and 45.45% for the Company.

In April 2010 Nordic filed a Schedule 13D/A (the “Amended 13D”) with the SEC. The Company is not in agreement with the Amended 13D and has written a letter to Nordic explaining its disagreements. The Amended 13D shows an aggregate number of shares of the Company’s common stock beneficially owned by Nordic of 216,666,666, or 65.5%. The Company believes the correct beneficial ownership is 85,714,286 shares, or 42.9%. The Amended 13D/A states that Nordic does not believe the Company’s determination of the anti-dilution shares accruing to Nordic as a result of the 2010 Equity Financing was neither reasonable nor made in good faith. As the Company has previously stated we believe our determination was both reasonable and made in good faith. The Amended 13D/A further states that Nordic acquired the right to purchase an additional 5,555,556 shares of the Company’s common stock upon exercise of the Nordic Put as a result of Nordic’s making an additional investment in the Hedrin JV of \$500,000 in January 2010. The Company is not in agreement with this claim and there is no adjustment to Nordic’s Put as a result of Nordic making additional capital contributions to the Hedrin JV. In the letter to Nordic the Company also points out that Nordic’s valuation suggestions for the warrants issued in the 2010 Equity Financing ignore the concept of relative value inherent in the Hedrin JV Agreement.

In July 2010, Nordic delivered a written notice to the Company for a \$500,000 capital increase to the Hedrin JV and made a \$500,000 capital contribution. No valuation has been set yet for this capital contribution. Manhattan's ownership interest will be reduced once the valuation for this capital contribution is set.



MANHATTAN PHARMACEUTICALS, INC. and SUBSIDIARY  
(a Development Stage Company)  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

In a letter dated October 19, 2010, addressed to the Hedrin JV, Thornton & Ross (which licenses certain intellectual property with respect to the Hedrin product to the Hedrin JV) made a demand for assurances and alleged that the Hedrin JV has not used commercially reasonable efforts to develop and secure marketing authorization for the Hedrin product and that the Hedrin JV does not have the financial means to perform even the most basic obligations under the License Agreement between Thornton & Ross and the Hedrin JV. The assurances that Thornton & Ross demand are: (1) a realistic and comprehensive clinical development plan through FDA approval of the Hedrin product, (2) an aggressive, yet realistic, development plan and timetable through Hedrin product launch, (3) enforceable funding commitments from a liquid source initially of up to \$5 million, and (4) new management with the necessary experience and commitment to move this program to successful commercialization.

To the Company's knowledge, the Hedrin JV has not yet formally responded to Thornton & Ross. Our knowledge of the Hedrin JV's efforts to develop and secure marketing authorization for the Hedrin product, however, is limited from and after August 18, 2010, as the Company has been denied its right to actively participate in the Hedrin JV from and after that date. (This is part of the disputes with Nordic that the Company is currently trying to resolve.) The Company believes that subsequent to August 18, 2010, representatives of Nordic and Thornton & Ross met, although no minutes of that meeting have been provided to the Company. Notwithstanding the Company's disputes with Nordic, the Company expects to work with Nordic to cause the Hedrin JV to respond to the Thornton & Ross letter within 30 days of its receipt by the Hedrin JV.

6. NOTES PAYABLE

The following is a summary of Notes Payable:

	At September 30, 2010			At December 31, 2009		
	Current portion, net	Noncurrent portion, net	Total	Current portion, net	Noncurrent portion, net	Total
Secured 12% Notes Payable	\$ 1,703,312	\$ -	\$ 1,703,312	\$ 1,247,062	\$ 384,473	\$ 1,631,535
8% Note Payable	-	-	-	27,000	-	27,000
Non-interest Bearing Note Payable	-	226,900	226,900	-	211,901	211,901
Convertible 12% Note Payable	-	-	-	-	17,807	17,807
Convertible 5% Notes Payable	-	15,452,793	15,452,793	-	-	-
ICON Convertible Note Payable	333,333	500,000	833,333	-	-	-
<b>Total</b>	<b>\$ 2,036,645</b>	<b>\$ 16,179,693</b>	<b>\$ 18,216,338</b>	<b>\$ 1,274,062</b>	<b>\$ 614,181</b>	<b>\$ 1,888,243</b>

MANHATTAN PHARMACEUTICALS, INC. and SUBSIDIARY  
(a Development Stage Company)  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

a. Secured 12% Notes Payable

On November 19, 2008, December 23, 2008 and February 3, 2009, the Company completed the first, second and final closings on a financing transaction (the "Secured 12% Notes Transaction"). The Company sold \$1,725,000 of 12% senior secured notes (the "Secured 12% Notes") and issued warrants to the investors to purchase 57.5 million shares of the Company's common stock at \$0.09 per share. The warrants expire on December 31, 2013. Net proceeds of \$1.4 million were realized from the three closings. In addition, \$78,000 of issuance costs were paid outside of the closings.

National Securities Corporation ("National") was the placement agent for the Secured 12% Notes Transaction. National's compensation for acting as placement agent was a cash fee of 10% of the gross proceeds received, a non-accountable expense allowance of 1.5% of the gross proceeds, reimbursement of certain expenses and a warrant to purchase such number of shares of the Company's common stock equal to 15% of the shares underlying the warrants issued to the investors. The Company paid National a total of \$202,000 in placement agent fees, a non-accountable expense allowance and reimbursement of certain expenses. In addition, the Company issued warrants to purchase 8.6 million shares of the Company's common stock at \$0.09 per share. These warrants were valued at \$29,110 and are a component of Secured 12% notes payable issue costs. The warrants expire on December 31, 2013.

The Secured 12% Notes mature two years after issuance. Interest on the Secured 12% Notes is compounded quarterly and payable at maturity. At September 30, 2010 and December 31, 2009, accrued and unpaid interest on the Secured 12% Notes amounted to approximately \$415,000 and \$229,000, and is reflected in the accompanying balance sheets at September 30, 2010 and December 31, 2009, respectively, as part of interest payable. The Secured 12% Notes are secured by a pledge of all of the Company's assets except for its investment in the Hedrin JV. In addition, to provide additional security for the Company's obligations under the notes, the Company entered into a default agreement, which provides that upon an event of default under the notes, the Company shall, at the request of the holders of the notes, use reasonable commercial efforts to either (i) sell a part or all of the Company's interests in the Hedrin joint venture or (ii) transfer all or part of the Company's interest in the Hedrin JV to the holders of the notes, as necessary, in order to fulfill the Company's obligations under the notes, to the extent required and to the extent permitted by the applicable Hedrin joint venture agreements.

In connection with the private placement, the Company, the placement agent and the investors entered into a registration rights agreement. Pursuant to the registration rights agreement, we agreed to file a registration statement to register the resale of the shares of our common stock issuable upon exercise of the warrants issued to the investors in the private placement, within 20 days of the final closing date and to cause the registration statement to be declared effective within 90 days (or 120 days upon full review by the Securities and Exchange Commission). During the year ended December 31, 2009 we filed the registration statement, received a comment letter from the SEC and responded to the comment letter from the SEC. The registration statement was declared effective on April 17, 2009.

The Company incurred a total of approximately \$424,000 of costs in the issuance of the \$1,725,000 of Secured 12% Notes sold in 2008 and 2009. These costs were capitalized and are being amortized over the life of the Secured 12% Notes into interest expense. During the nine months ended September 30, 2010 and the year ended December 31, 2009, the amount amortized into interest expense was approximately \$157,000 and \$206,000, respectively. The remaining unamortized balance of approximately \$44,000 and \$201,000 is reflected in the accompanying balance sheets as of September 30, 2010 and December 31, 2009, respectively, as debt issue costs.

The Company recognized an original issue discount (the "OID") of approximately \$194,000 on the issuance of the Secured 12% Notes sold for the value of the warrants issued to the investors. The OID is being amortized over the life of the Secured 12% Notes into interest expense. During the nine months ended September 30, 2010 and year ended December 31, 2009 the amount amortized into interest expense was approximately \$72,000 and \$94,000, respectively. The remaining unamortized balance of approximately \$22,000 and \$93,000 has been netted against the face amount of Notes Payable in the accompanying balance sheets as of September 30, 2010 and December 31, 2009, respectively.

MANHATTAN PHARMACEUTICALS, INC. and SUBSIDIARY  
(a Development Stage Company)  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

b. 8% Note Payable

On December 21, 2009, the Company entered into a Future Advance Promissory Note (the “8% Note”) with Ariston under which the Company may withdraw up to \$67,000 bearing interest at a rate of 8%. As of December 31, 2009, the Company had withdrawn \$27,000 from Ariston subject to the terms of the 8% Note. On January 13, 2010, the Company withdrew an additional \$20,000 subject to the 8% Note and on January 28, 2010, the Company withdrew an additional \$20,000 subject to the 8% Note.

On March 4, 2010, the Company repaid Ariston the \$67,000 withdrawn subject to the 8% Note and accrued interest of \$816.

c. Non-interest Bearing Note Payable

On October 27, 2009, the Company entered into a Settlement Agreement and Mutual Release with Swiss Pharma Contract LTD (“Swiss Pharma”) pursuant to which the Company agreed to pay Swiss Pharma \$200,000 and issue to Swiss Pharma an interest free promissory note in the principal amount of \$250,000 in full satisfaction of the September 5, 2008 arbitration award. The amount of the Arbitration award was \$683,027 at September 30, 2009 and was included as a component of accrued expenses.

In connection with the non-interest bearing note, the Company recognized an original issue discount of \$40,000 of imputed interest on the note, which is being amortized into interest expense on a straight-line basis over the two-year term of the note. For the nine months ended September 30, 2010 and the year ended December 31, 2009, the Company amortized \$15,000 and \$1,900 of the OID into interest expense, respectively. The remaining unamortized balance of \$23,100 has been netted against the face amount of Notes Payable in the accompanying balance sheet as of September 30, 2010.

d. Convertible 12% Note Payable

In October 2009, the Company entered into a Subscription Agreement (the “Subscription Agreement”) pursuant to which it sold a 12% Original Issue Discount Senior Subordinated Convertible Debenture with a stated value of \$400,000 (the “Convertible 12% Note”) and a warrant to purchase 2,222,222 shares of the Company’s common stock, par value \$.001 per share for a purchase price of \$200,000. The Convertible 12% Note is convertible into shares of Common Stock at an initial conversion price of \$0.09 per share, subject to adjustment, or, in the event the Company issues new securities in connection with a financing, the Convertible 12% Note may be converted into such new securities at a conversion price equal to the purchase price paid by the purchasers of such new securities. The Company may also, in its sole discretion, elect to pay interest due on the Convertible 12% Note quarterly in shares of the Company’s common stock provided such shares are subject to an effective registration statement. The Convertible 12% Note is subordinated to the Company’s outstanding Secured 12% Notes. The Warrant is exercisable at an exercise price of \$0.11 per share, subject to adjustment. Because the Convertible 12% Note and the Warrant are convertible into shares of the Company, subject to adjustment, the conversion feature is subject to Derivative Liability accounting (see Note 8).

National was the placement agent for the Convertible 12% Note transaction. In connection with the issuance of the Securities, the Company issued warrants to purchase an aggregate of 222,222 shares of Common Stock at an exercise price of \$0.11 per share, subject to adjustment, to the placement agent and certain of its designees. Because the warrant is convertible into shares of the Company, subject to adjustment, the warrants are subject to Derivative Liability accounting (see Note 8). The warrants expire on October 28, 2014.

The Convertible 12% Notes mature two years after issuance. Interest on the Convertible 12% Note is compounded quarterly and payable at maturity. At December 31, 2009, accrued and unpaid interest on the Convertible 12% Note amounted to approximately \$9,000, and is reflected in the accompanying balance sheet at December 31, 2009 as a component of interest payable.

On April 8, 2010, the holder (the "Noteholder") of the outstanding Convertible 12% Note, dated October 28, 2009, with a stated value of \$400,000 and \$22,000 of accrued interest, exercised its option to convert its note (including all accrued interest thereon into 16.88 Units (as described in Note 7). The conversion price was equal to the per Unit purchase price paid by the Investors in the private placement. As a result of this conversion, the Company accelerated the amortization of approximately \$30,000 in issue costs and \$160,000 original issue discount, which is reflected as a loss on early extinguishment in the accompanying statement of operations for the nine months ended September 30, 2010.

MANHATTAN PHARMACEUTICALS, INC. and SUBSIDIARY  
(a Development Stage Company)  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

e. Convertible 5% Notes Payable

Upon the Merger, Ariston issued \$15,452,793 of five-year 5% notes payable (the "5% Notes Payable") in satisfaction of several note payable issuances. The cumulative liability including accrued and unpaid interest of these several issuances of notes was \$15,452,793 as of the Merger date. Interest is payable at maturity and compounds annually. The 5% Notes Payable and accrued and unpaid interest thereon are convertible at the option of the holder into the Manhattan's common stock at the conversion price of \$0.40 per share. Ariston agreed to make quarterly payments on the 5% Notes Payable equal to 50% of the gross proceeds resulting from the revenues received from the exploitation or commercialization of Ariston's product candidates, AST-726 and AST-915. The 5% Notes Payable are solely the obligation of Ariston and have no recourse to Manhattan other than the conversion feature discussed above. For the nine months ended September 30, 2010, the Company recorded approximately \$434,000 in accrued interest, which is reflected as a component of interest payable in the accompanying balance sheet as of September 30, 2010.

f. ICON Convertible Note Payable

Upon the Merger, Ariston satisfied an account payable of \$1,275,188 to ICON Clinical Research Limited through the payment of \$275,188 in cash and the issuance of a three-year 5% note payable (the "ICON Note Payable"). The principal is to be repaid in 36 monthly installments of \$27,778 commencing in April 2010. Interest is payable monthly in arrears. The ICON Convertible Note Payable is convertible at the option of the holder into the Company's common stock at the conversion price of \$0.20 per share. During the nine months ended September 30, 2010, the Company has paid approximately \$193,000 in principal and interest to ICON. For the nine months ended September 30, 2010, the Company recorded approximately \$26,000 in interest expense as reflected on the accompanying statement of operations for the nine months ended September 30, 2010.

7. 2010 EQUITY FINANCING

On March 2, 2010, the Company raised aggregate gross proceeds of approximately \$2,547,500 pursuant to a private placement of its securities (the "2010 Equity Financing"). The Company entered into subscription agreements (the "Subscription Agreements") with seventy-seven accredited investors (the "Investors") pursuant to which the Company sold an aggregate of 101.9 Units (as defined herein) for a purchase price of \$25,000 per Unit. Pursuant to the Subscription Agreements, the Company issued to each Investor units (the "Units") consisting of (i) 357,143 shares of common stock, \$0.001 par value per share (the "Common Stock" or "Shares") of the Company and (ii) 535,714 warrants (each a "Warrant" and collectively the "Warrants"), each of which will entitle the holder to purchase one additional share of Common Stock for a period of five years (each a "Warrant Share" and collectively the "Warrant Shares") at an exercise price of \$0.08 per share. Because the Warrant Shares are convertible into shares of the Company, subject to adjustment, the conversion feature is subject to Derivative Liability accounting (see Note 8).

National was the placement agent for the 2010 Equity Financing transaction. In connection with the issuance of the Securities, the Company issued warrants to purchase an aggregate of 3,369,289 shares of Common Stock at an exercise price of \$0.08 per share, subject to adjustment, to the placement agent and certain of its designees. Because the warrant is convertible into shares of the Company, subject to adjustment, the warrants are subject to Derivative Liability accounting (see Note 8). The warrants expire on March 2, 2015.

The Nordic Put and Nordic Warrant were issued at a value of \$0.14 per share and were issued with anti-dilution rights. The issuance of any securities at a value of less than \$0.14 per share activates Nordic's anti-dilution rights. The Secured 12% Note transaction included warrants with an exercise price of \$0.09 per share, this activated Nordic's

anti-dilution rights as reflected in the table below under the caption “Before the Equity Pipe Transaction”. Any issuances of any securities subsequent to the Secured 12% Note transaction at a value of less than \$0.09 further activates Nordic’s anti-dilution rights. The Equity Pipe transaction in March 2010 effectively included the sale of one share of common stock and a warrant to purchase 1.5 shares of common stock for a price of \$0.07. The JV Agreement between Nordic and Manhattan governs the antidilution protection to Nordic. Section 5.1 of that agreement state “If shares of Common Stock or Common Stock Equivalents are issued or sold together with other stock or securities or other assets of MHA (Manhattan) for a consideration which covers both, the effective price per share shall be computed with regard to the portion of the consideration so received that may reasonably be determined in good faith by the Board of Directors, to be allocable to such Common Stock or Common Stock Equivalent.” The good faith determination of the effective price per share was \$0.07 for each share of common stock sold and a de minimus value to the warrants. The Nordic Put and the Nordic Warrant are now valued at a price of \$0.07 per share.

MANHATTAN PHARMACEUTICALS, INC. and SUBSIDIARY  
(a Development Stage Company)  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The following table shows the effect of Nordic's anti-dilution rights.

	Shares Issuable Upon Exercise of Nordic's Put	Shares Issuable Upon Exercise of Nordic's Warrant	Total Shares Issuable Upon Exercise of Nordic's Put and Warrant
Before the Equity Pipe Transaction	55,555,556	11,111,111	66,666,667
Antidilution shares	15,873,015	3,174,603	19,047,618
After the Equity Pipe Transaction	71,428,571	14,285,714	85,714,285

In March 2010, we received correspondence from Nordic that questions how we calculated the anti-dilution shares, as shown above, and suggesting that we did not employ a good faith estimate. We believe our determination was made in good faith and is appropriate. (See Note 5.)

All of the Investors represented that they were "accredited investors," as that term is defined in Rule 501(a) of Regulation D under the Securities Act, and the sale of the Units was made in reliance on exemptions provided by Regulation D and Section 4(2) of the Securities Act of 1933, as amended.

In connection with the closing of the private placement, the Company, the placement agent acting in connection with the private placement (the "Placement Agent") and the Investors entered into a Registration Rights Agreement, dated as of March 2, 2010, and the Company agreed to file a registration statement to register the resale of the Shares, within 60 days of the final closing date and to cause the registration statement to be declared effective within 150 days (or 180 days upon review by the SEC).

The Company received net proceeds of approximately \$2,100,000 after payment of an aggregate of approximately \$300,000 of commissions and expense allowance to the Placement Agent, and approximately \$100,000 of other offering and related costs in connection with the private placement. In addition, the Company issued a warrant to purchase 3,639,289 shares of Common Stock at an exercise price of \$0.08 per share to the Placement Agent as additional compensation for its services.

The Company did not use any form of advertising or general solicitation in connection with the sale of the Units. The Shares, the Warrants and the Warrant Shares are non-transferable in the absence of an effective registration statement under the Act, or an available exemption therefrom, and all certificates are imprinted with a restrictive legend to that effect.

On April 8, 2010, the Company completed the final closing of the 2010 Equity Financing. In connection with the final closing, the Company sold an aggregate of 2.4 additional Units and received net proceeds of approximately \$51,700 after payment of an aggregate of \$8,300 of commissions and expense allowance to placement agent. In connection with the final closing, the Company also issued a warrant to purchase 12,857 shares of Common Stock at an exercise price of \$0.08 per share to the placement agent as additional compensation for its services.

In addition on April 8, 2010, the holder of the Convertible 12% Note (see Note 6) with a stated value of \$400,000 and \$22,000 of accrued interest, exercised its option to convert its Debenture (including all accrued interest thereon) into 16.88 Units. The conversion price was equal to the per Unit purchase price paid by the Investors in the private placement.



The Company issued a total of 6,885,717 shares of common stock and warrants to purchase 10,328,566 shares of common stock at an exercise price of \$0.08 per share to the investors in the final closing of the 2010 Equity Financing, including the conversion of the 12% Convertible Note.

MANHATTAN PHARMACEUTICALS, INC. and SUBSIDIARY  
(a Development Stage Company)  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

8. DERIVATIVE LIABILITY

In April 2008, the FASB issued ASC 815 which provides guidance on determining what types of instruments or embedded features in an instrument held by a reporting entity can be considered indexed to its own stock for the purpose of evaluating the first criteria of the scope exception in the pronouncement on accounting for derivatives. This pronouncement was effective for financial statements issued for fiscal years beginning after December 15, 2008. The adoption of these requirements can affect the accounting for warrants and many convertible instruments with provisions that protect holders from a decline in the stock price (or “down-round” provisions). For example, warrants with such provisions will no longer be recorded in equity. Down-round provisions reduce the exercise price of a warrant or convertible instrument if a company either issues equity shares for a price that is lower than the exercise price of those instruments or issues new warrants or convertible instruments that have a lower exercise price. We evaluated whether warrants to acquire stock of the Company contain provisions that protect holders from declines in the stock price or otherwise could result in modification of the exercise price under the respective warrant agreements. We determined that the warrant issued to Nordic in April 2008 (the “Nordic Warrant”), the warrants issued in connection with the 2009 sale of the Convertible 12% Note Payable and its subsequent conversion in April 2010, and the warrants issued in connection with the 2010 Equity Financing contained such provisions, thereby concluding they were not indexed to the Company’s own stock and were reclassified from equity to derivative liabilities.

In accordance with ASC 815, the Company estimated the fair value of the Nordic Warrant as of January 1, 2009 to be \$22,222 by recording a reduction in additional paid-in capital of \$150,000 and a decrease in deficit accumulated during the development stage of \$127,778. The effect of this adjustment is recorded as a cumulative effect of change in accounting principle in our statements of stockholders’ equity (deficiency). As of September 30, 2010, the fair value of these derivatives was \$198,571 as recorded in the accompanying balance sheet as of September 30, 2010, as a component of a current liability, derivative liability. The change of \$(151,429) and \$(284,762) in fair value during the three and nine months ended September 30, 2010, respectively, is reported as a noncash charge in the accompanying consolidated statements of operations as a component of other (income) expense.

In accordance with ASC 815 the Company estimated the fair value at the date of issuance of the conversion feature of the Convertible 12% Note and the fair value of the related warrants to purchase 2,444,444 shares of the Company’s common stock at \$175,100 and \$27,390, respectively. On April 8, 2010, the holder of the Convertible 12% Note exercised his option to convert. As a result, the derivative liability associated with the notes were reclassified to Convertible 12% Note Payable with the change in fair value from the date of issuance \$29,506 reclassified as a loss on early extinguishment of debt in the accompanying statement of operations for the nine months ended September 30, 2010. As of September 30, 2010 the fair value of these derivatives related to the warrants outstanding totaled \$39,600 and are recorded in the accompanying balance sheet as of September 30, 2010 as a component of derivative liability. The change in fair value of \$(28,356) and \$(81,400) during the three and nine months ended September 30, 2010, respectively, is reported as a non-cash charge in the accompanying consolidated statements of operations as a component of other (income) expense.

In addition, in accordance with ASC 815, the Company estimated the fair value at the date of issuance of the 9,042,853 warrants issued in connection with the conversion of the Convertible 12% Note at \$528,103. As of September 30, 2010, the fair value of these derivatives was \$151,016 as recorded in the accompanying balance sheet as of September 30, 2010, as a component of a current liability, derivative liability. The change in fair value of \$(85,002) and \$(377,086) in fair value during the three and nine months ended September 30, 2010, respectively, is reported as a non-cash charge in the accompanying consolidated statements of operations as a component of other

(income) expense.

Additionally, in accordance with ASC 815 the Company estimated the fair value at the date of issuance of the 54,589,266 warrants issued in connection with the 2010 Equity Financing and the fair value of the related 3,369,289 warrants issued to the placement agents in the 2010 Equity Financing at \$2,713,087 and \$180,873, respectively. As of September 30, 2010 the fair value of these derivatives totaled \$949,125 and are recorded in the accompanying consolidated balance sheet as of September 30, 2010 as a component of derivative liability. The change in fair value of \$(553,171) and \$(1,944,835) during the three and nine months ended September 30, 2010, respectively, is reported as a non-cash charge in the accompanying consolidated statements of operations as a component of other (income) expense.

MANHATTAN PHARMACEUTICALS, INC. and SUBSIDIARY  
(a Development Stage Company)  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Additionally, in accordance with ASC 815 the Company estimated the fair value at the date of issuance of the 1,285,714 warrants issued in connection with the final closing of the 2010 Equity Financing in April 2010 and the fair value of the related 12,857 warrants issued to the placement agents in the final closing of the 2010 Equity Financing at \$75,086 and \$751, respectively. As of September 30, 2010 the fair value of these derivatives totaled \$21,686 and are recorded in the accompanying consolidated balance sheet as of September 30, 2010 as a component of derivative liability. The change in fair value of \$(12,207) and \$(54,151) during the three and nine months ended September 30, 2010, respectively, is reported as a non-cash charge in the accompanying consolidated statements of operations as a component of other (income) expense.

9. SUBSEQUENT EVENT

On November 8, 2010, the Company was awarded \$244,279 in funding under the U.S. Government's Qualifying Therapeutic Discovery Project ("QTDP") credit program. The Company has received this funding for its lead product candidate AST-726 for the treatment of vitamin B12 deficiency.

The QTDP was created by Congress in March 2010, as enacted under the Patient Protection and Affordable Care Act, and provides a tax credit or grant equal to 50% of eligible costs and expenses for the tax years 2009 and 2010. The QTDP was designed to promote medical research and innovation that could improve health and save lives. The program targeted projects in new innovative therapies to prevent, diagnose, and treat acute and chronic diseases. Companies that received QTDP grants were selected jointly by the Treasury Department and the Department of Health and Human Services. The grants were limited to companies with 250 or fewer employees.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion of our results of operations and financial condition in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2009 (the "Annual Report") and our financial statements for the nine month period ended September 30, 2010 included elsewhere in this report.

We were incorporated in Delaware in 1993 under the name "Atlantic Pharmaceuticals, Inc." and, in March 2000, we changed our name to "Atlantic Technology Ventures, Inc." In 2003, we completed a "reverse acquisition" of privately held "Manhattan Research Development, Inc". In connection with this transaction, we also changed our name to "Manhattan Pharmaceuticals, Inc." From an accounting perspective, the accounting acquirer is considered to be Manhattan Research Development, Inc. and accordingly, the historical financial statements are those of Manhattan Research Development, Inc.

During 2005 we merged with Tarpan Therapeutics, Inc. ("Tarpan"). Tarpan was a privately held New York based biopharmaceutical company developing dermatological therapeutics. This transaction was accounted for as a purchase of Tarpan by the Company.

On March 8, 2010, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Company, Ariston Pharmaceuticals, Inc., a Delaware corporation ("Ariston") and Ariston Merger Corp., a Delaware corporation and wholly-owned subsidiary of the Company (the "Merger Sub"). Pursuant to the terms and conditions set forth in the Merger Agreement, on March 8, 2010, the Merger Sub merged with and into Ariston (the "Merger"), with Ariston being the surviving corporation of the Merger. As a result of the Merger, Ariston became a wholly-owned subsidiary of the Company. The operating results of Ariston from March 8, 2010 to September 30, 2010 are included in the accompanying Condensed Consolidated Statements of Operations. The Condensed Consolidated Balance Sheet as of September 30, 2010 reflects the acquisition of Ariston, effective March 8, 2010, the date of the Merger.

We are a specialty healthcare product company focused on developing and commercializing pharmaceutical treatments for underserved patient populations. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding their research and development and eventually either bringing the technologies to market or out-licensing.

This discussion includes "forward-looking" statements that reflect our current views with respect to future events and financial performance. We use words such as we "expect," "anticipate," "believe," and "intend" and similar expressions to identify forward-looking statements. Investors should be aware that actual results may differ materially from our expressed expectations because of risks and uncertainties inherent in future events, particularly those risks identified under the heading "Risk Factors" following Item 1 in the Annual Report, and should not unduly rely on these forward looking statements.

## Results of Operations

Nine-month Periods ended September 30, 2010 vs 2009:

	Nine months ended September 30,		Increase/	% Increase/
	2010	2009	(decrease)	(decrease)
<b>Costs and expenses:</b>				
<b>Research and development:</b>				
Share-based compensation	\$ -	\$ 1,000	\$ (1,000)	-100.00%
Other research and development expenses	305,000	56,000	249,000	444.64%
<b>Total research and development expenses</b>	<b>305,000</b>	<b>57,000</b>	<b>248,000</b>	<b>435.09%</b>
<b>General and administrative:</b>				
Share-based compensation	212,000	270,000	(58,000)	-21.48%
Other general and administrative expenses	1,053,000	1,103,000	(50,000)	-4.53%
<b>Total general and administrative expenses</b>	<b>1,265,000</b>	<b>1,373,000</b>	<b>(108,000)</b>	<b>-7.87%</b>
<b>Other income/(expense):</b>				
Equity in losses of Hedrin JV	-	(337,000)	337,000	-100.00%
Change in fair value of derivative liability	2,697,000	(659,000)	3,356,000	-509.26%
Loss on early extinguishment of debt	(159,000)	-	(159,000)	N/A
Interest expense	(938,000)	(397,000)	(541,000)	136.27%
Interest and other income	228,000	253,000	(25,000)	-9.88%
<b>Total other income/(expense)</b>	<b>1,828,000</b>	<b>(1,140,000)</b>	<b>2,968,000</b>	<b>-260.35%</b>
<b>Net income/(loss)</b>	<b>\$ 258,000</b>	<b>\$ (2,570,000)</b>	<b>\$ 2,828,000</b>	<b>-110.04%</b>

During each of the nine month periods ended September 30, 2010 and 2009, we did not recognize any revenues. We are considered a development stage company and do not expect to have revenues relating to our products candidates prior to September 30, 2011, if at all.

For the nine months ended September 30, 2010 research and development expense was \$305,000 as compared to \$57,000 for the nine months ended September 30, 2009. This increase of \$248,000, or 435%, is primarily due to commencement of development activity on our AST-726 project during the 2010 period and limited product development activity during the 2009 period.

For the nine months ended September 30, 2010 general and administrative expense was \$1,265,000 as compared to \$1,373,000 for the nine months ended September 30, 2009. This decrease of \$108,000, or 8%, is primarily due to a reduction in staff.

For the nine months ended September 30, 2010 other income/(expense) was \$1,828,000 as compared to \$(1,140,000) for the nine months ended September 30, 2009. This change of \$2,968,000, or (260)%, is primarily due to a change in fair value of derivative liability of \$3,356,000 and a decrease in equity in losses of Hedrin JV of \$337,000, offset by an increase in interest expense of \$541,000, an increase of \$159,000 in loss on early extinguishment of debt and a decrease in other income of \$25,000. The increase in interest expense is due to the increase in interest bearing debt of the Company resulting from the Ariston Merger.

Edgar Filing: MANHATTAN PHARMACEUTICALS INC - Form 10-Q

Net income for the nine months ended September 30, 2010 was \$258,000 as compared to a net loss of \$2,570,000 for the nine months ended September 30, 2009. This change of \$2,828,000, or (110)%, is primarily due to a change in fair value of derivative liability of \$3,356,000, offset by an increase in interest expense of \$541,000.

Three-month Periods ended September 30, 2010 vs 2009:

	Three months ended September 30,		Increase/	% Increase/
	2010	2009	(decrease)	(decrease)
<b>Costs and expenses:</b>				
<b>Research and development:</b>				
Share-based compensation	\$ -	\$ -	\$ -	N/A
Other research and development expenses	236,000	5,000	231,000	4620.00%
<b>Total research and development expenses</b>	<b>236,000</b>	<b>5,000</b>	<b>231,000</b>	<b>4620.00%</b>
<b>General and administrative:</b>				
Share-based compensation	6,000	78,000	(72,000)	-92.31%
Other general and administrative expenses	273,000	312,000	(39,000)	-12.50%
<b>Total general and administrative expenses</b>	<b>279,000</b>	<b>390,000</b>	<b>(111,000)</b>	<b>-28.46%</b>
<b>Other income/(expense):</b>				
Equity in losses of Hedrin JV	-	(105,000)	105,000	N/A
Change in fair value of derivative liability	830,000	158,000	672,000	425.32%
Loss on early extinguishment of debt	-	-	-	N/A
Interest expense	(350,000)	(138,000)	(212,000)	153.62%
Interest and other income	76,000	64,000	12,000	18.75%
<b>Total other income/(expense)</b>	<b>556,000</b>	<b>(21,000)</b>	<b>577,000</b>	<b>-2747.62%</b>
<b>Net income/(loss)</b>	<b>\$ 41,000</b>	<b>\$ (416,000)</b>	<b>\$ 457,000</b>	<b>-109.86%</b>

For the three months ended September 30, 2010 research and development expense was \$236,000 as compared to \$5,000 for the three months ended September 30, 2009. This increase of \$231,000, or 4,620%, is primarily due to commencement of development activity on our AST-726 project during the 2010 period and limited product development activity during the 2009 period.

For the three months ended September 30, 2010 general and administrative expense was \$279,000 as compared to \$390,000 for the three months ended September 30, 2009. This decrease of \$111,000, or 28%, is primarily due to a reduction in share-based compensation.

For the three months ended September 30, 2010 other income/(expense) was \$556,000 as compared to \$(21,000) for the three months ended September 30, 2009. This change of \$577,000, or 2748%, is primarily due to changes in the fair value of a derivative of \$672,000 and equity in losses of Hedrin JV of \$105,000, offset by an increase in interest expense of \$212,000. The increase in interest expense is due to the increase in interest bearing debt of the Company resulting from the Ariston Merger.

Net income for the three months ended September 30, 2010 was \$41,000 as compared to a net loss of \$416,000 for the three months ended September 30, 2009. This change of \$457,000, or (111)%, is primarily due to a change in fair value of derivative liability of \$672,000, which resulted from a decrease in the market price of our stock, a decrease in general and administrative expense of \$111,000, offset by increases in research and development expense of \$231,000 and interest expense of \$212,000.

#### Liquidity and Capital Resources

From inception to September 30, 2010, we incurred a deficit during the development stage of \$61,675,000 primarily as a result of our net losses, and we expect to continue to incur additional losses through at least September 30, 2011 and for the foreseeable future. These losses have been incurred through a combination of research and development



activities related to the various technologies under our control and expenses supporting those activities.

We have financed our operations since inception primarily through equity and debt financings and a joint venture transaction. During the nine months ended September 30, 2010, we had a net increase in cash and cash equivalents of \$1.1 million. This increase resulted largely from net cash provided by financing activities of \$2.2 million and \$0.5 million of cash acquired in the Ariston merger partially offset by net cash used in operating activities of \$1.4 million and the repayment of \$0.2 million of debt. Total liquid resources as of September 30, 2010 were \$1.1 million compared to \$18,000 at December 31, 2009.

Our current liabilities as of September 30, 2010 were \$4,208,000 compared to \$2,532,000 at December 31, 2009, an increase of \$1,676,000. As of September 30, 2010, we had working capital deficit of \$2,940,000 compared to working capital deficit of \$2,268,000 at December 31, 2009.

The Company received net proceeds of approximately \$2,200,000 in March and April 2010 from the 2010 Equity Financing. In addition \$400,000 principal amount of debt converted into the 2010 Equity Financing. The Company also acquired \$519,000 of cash in the merger with Ariston and repaid \$194,000 of debt.

Our available working capital and capital requirements will depend upon numerous factors, including progress of our research and development programs, our progress in and the cost of ongoing and planned nonclinical and clinical testing, the timing and cost of obtaining regulatory approvals, the cost of filing, prosecuting, defending, and enforcing patent claims and other intellectual property rights, in-licensing activities, competing technological and market developments, changes in our existing collaborative and licensing relationships, the resources that we devote to developing manufacturing and commercializing capabilities, the status of our competitors, our ability to establish collaborative arrangements with other organizations and our need to purchase additional capital equipment.

Our continued operations will depend on whether we are able to raise additional funds through various potential sources, such as equity and debt financing, other collaborative agreements, strategic alliances, and our ability to realize the full potential of our technology in development. Such additional funds may not become available on acceptable terms and there can be no assurance that any additional funding that we do obtain will be sufficient to meet our needs in the long term. Through September 30, 2010, a significant portion of our financing has been through private placements of debt, common stock and warrants. Unless our operations generate significant revenues and cash flows from operating activities, we will continue to fund operations from cash on hand and through the similar sources of capital previously described. We can give no assurances that any additional capital that we are able to obtain will be sufficient to meet our needs. We believe that we will continue to incur net losses and negative cash flows from operating activities for the foreseeable future.

Based on the resources of the Company available at September 30, 2010, management believes that the Company has sufficient capital to fund its operations through 2010. Management believes that the Company will need additional equity or debt financing or will need to generate positive cash flow from the Hedrin JV, or generate revenues through licensing of its products or entering into strategic alliances to be able to sustain its operations into 2011. Furthermore, the Company will need additional financing thereafter to complete development and commercialization of its products. There can be no assurances that we can successfully complete development and commercialization of our products. In addition, \$1,725,000 principal amount of debt plus interest thereon matures in three tranches beginning in November 2010. The Company does not have the funds to repay this debt and is negotiating with representatives of the debt holders for either an extension of the maturity date or a conversion into of the debt into equity. If the Company cannot reach agreement with the debt holders the Company will be in default on the debt.

In November 2010 \$1,316,000 of principal and interest matures, in December 2010 \$356,000 of interest and principal matures and in February 2011 \$521,000 of principal and interest matures. If the Company defaults on these debt obligations the debtholders have the right to appoint a collateral agent and have that collateral agent foreclose on the collateral. The collateral is principally comprised of Manhattan's investment in Ariston and the Company's interest in the Hedrin JV. Foreclosure on the collateral would render the Company bankrupt. If the Company cannot reach agreement with the debtholders the Company may have to file for voluntary bankruptcy.

The Company does not have the financial resources necessary to conduct the pivotal trial of AST-726 and will have to raise funds for that purpose.

These matters raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

We have reported net income of \$258,000 for the nine month periods ended September 30, 2010 and a net loss of \$2,570,000 for the nine month periods ended September 30, 2009. The net income for the nine month period in 2010 resulted from a decrease in the Company's derivative liability. Without this decrease, which was principally caused by a decrease in the market price of our common stock, the Company would have sustained a loss during the 2010 period. The net loss attributable to common shares from date of inception, including preferred stock dividends, August 6, 2001 to September 30, 2010, amounts to \$61,675,000. Management believes that we will continue to incur net losses through at least September 30, 2011.

## Joint Venture Agreement

We and Nordic Biotech Venture Fund II K/S, or Nordic, entered into a joint venture agreement on January 31, 2008, which was amended on February 18, 2008 and on June 9, 2008. Pursuant to the joint venture agreement, in February 2008, (i) Nordic contributed cash in the amount of \$2.5 million to H Pharmaceuticals K/S (formerly Hedrin Pharmaceuticals K/S), a newly formed Danish limited partnership, or the Hedrin JV, in exchange for 50% of the equity interests in the Hedrin JV, and (ii) we contributed certain assets to North American rights (under license) to our Hedrin product to the Hedrin JV in exchange for \$2.0 million in cash and 50% of the equity interests in the Hedrin JV. On or around June 30, 2008, in accordance with the terms of the joint venture agreement, Nordic contributed an additional \$1.25 million in cash to the Hedrin JV, \$1.0 million of which was distributed to us and equity in the Hedrin JV was distributed to each of us and Nordic sufficient to maintain our respective ownership interests at 50%.

Pursuant to the joint venture agreement, upon the classification by the U.S. Food and Drug Administration, or the FDA, of Hedrin as a Class II or Class III medical device, Nordic was required to contribute to the Hedrin JV an additional \$1.25 million in cash, \$0.5 million of which was to be distributed to us and equity in the Hedrin JV was to be distributed to each of us and Nordic sufficient to maintain our respective ownership interests at 50%. The FDA notified the Hedrin JV that Hedrin has been classified as a Class III medical device and in February 2009, Nordic made the \$1.25 million investment in the Hedrin JV, the Hedrin JV made the \$0.5 million milestone payment to us and equity in the Hedrin JV was distributed to us and Nordic sufficient to maintain our respective ownership interests at 50%.

The Hedrin JV is responsible for the development and commercialization of Hedrin for the North American market and all associated costs including clinical trials, if required, regulatory costs, patent costs, and future milestone payments owed to Thornton & Ross Ltd., or T&R, the licensor of Hedrin. The Hedrin JV has engaged us to provide management services to the Hedrin JV in exchange for an annualized management fee, which for the nine month periods ended September 30, 2010 and 2009 was approximately \$225,000 and \$259,000, respectively.

The profits of the Hedrin JV will be shared by us and Nordic in accordance with our respective equity interests in the Hedrin JV, except that Nordic is entitled to receive a minimum return each year from the Hedrin JV equal to 6% on Hedrin sales, as adjusted for any change in Nordic's equity interest in the Hedrin JV, before any distribution is made to us. If the Hedrin JV realizes a profit in excess of the Nordic minimum return in any year, then such excess shall first be distributed to us until our distribution and the Nordic minimum return are in the same ratio as our respective equity interests in the Hedrin JV and then the remainder, if any, is distributed to Nordic and us in the same ratio as our respective equity interests. However, in the event of a liquidation of the Hedrin JV, Nordic's distribution in liquidation must equal the amount Nordic invested in the Hedrin JV plus 10% per year, less the cumulative distributions received by Nordic from the Hedrin JV before any distribution is made to us. If the Hedrin JV's assets in liquidation exceed the Nordic liquidation preference amount, then any excess shall first be distributed to us until our distribution and the Nordic liquidation preference amount are in the same ratio as our respective equity interests in the Hedrin JV and then the remainder, if any, is distributed to Nordic and us in the same ratio as our respective equity interests. Further, in no event shall Nordic's distribution in liquidation be greater than assets available for distribution in liquidation.

Pursuant to the terms of the joint venture agreement, Nordic has the right to nominate one person for election or appointment to our board of directors. Nordic has not exercised this right. The Hedrin JV's board of directors consists of four members, two members appointed by us and two members appointed by Nordic. Nordic has the right to appoint one of the directors as chairman of the board. The chairman has certain tie breaking powers.

Pursuant to the joint venture agreement, Nordic has the right to put all or a portion of the interest Nordic received in exchange for the first \$5 million Nordic invested in the Hedrin JV in exchange for such number of shares of our common stock equal to the amount of Nordic's investment in the Hedrin JV divided by \$0.07, as adjusted for the 2010

Equity Financing, and as further adjusted from time to time for stock splits and other specified events, multiplied by a conversion factor, which is (i) 1.00 for so long as Nordic's distributions from the Hedrin JV are less than the amount of its investment, (ii) 1.25 for so long as Nordic's distributions from the Hedrin JV are less than two times the amount of its investment but greater than or equal to the amount of its investment amount, (iii) 1.50 for so long as Nordic's distributions from the Hedrin JV are less than three times the amount of its investment but greater than or equal to two times the amount of its investment amount, (iv) 2.00 for so long as Nordic's distributions from the Hedrin JV are less than four times the amount of its investment but greater than or equal to three times the amount of its investment amount and (v) 3.00 for so long as Nordic's distributions from Hedrin JV are greater than or equal to four times the amount of its investment. The put right expires upon the earlier to occur of (i) February 25, 2018 and (ii) 30 days after the date when Nordic's distributions from the Hedrin JV exceed five times the amount Nordic has invested in the Hedrin JV (or 10 days after such date if we have provided Nordic notice thereof).

Pursuant to the joint venture agreement, we have the right to call all or a portion of Nordic's equity interest in the Hedrin JV in exchange for such number of shares of our common stock equal to the portion of Nordic's investment in the Hedrin JV that we call by the dollar amount of Nordic's investment as of such date in the Hedrin JV, divided by \$0.07, as adjusted for the sale of the Secured 12% Notes in the fourth quarter of 2008, and as further adjusted from time to time for stock splits and other specified events. The call right is only exercisable by us if the price of our common stock has closed at or above \$1.40 per share for 30 consecutive trading days. During the first 30 consecutive trading days in which our common stock closes at or above \$1.40 per share, we may exercise up to 25% of the call right. During the second 30 consecutive trading days in which our common stock closes at or above \$1.40 per share, we may exercise up to 50% of the call right on a cumulative basis. During the third consecutive 30 trading days in which our common stock closes at or above \$1.40 per share, we may exercise up to 75% of the call right on a cumulative basis. During the fourth consecutive 30 days in which our common stock closes at or above \$1.40 per share, we may exercise up to 100% of the call right on a cumulative basis. Nordic may refuse the call, either by paying \$1.5 million multiplied by the percentage of Nordic's investment being called or forfeiting an equivalent portion of the put right, calculated on a pro rata basis for the percentage of the Nordic equity interest called by us. The call right expires on February 25, 2013. For purposes of Nordic's right to put, and our right to call, all or a portion of Nordic's equity interest in the Hedrin JV, the amount of Nordic's investment is currently \$5,000,000.

In connection with our joint venture agreement, on February 25, 2008, Nordic paid us a non-refundable fee of \$150,000 in exchange for the right to receive a warrant to purchase up to 14,285,714 shares of our common stock at \$0.07 per share, as adjusted for the 2010 Equity Financing, and as further adjusted from time to time for stock splits and other specified events.

In connection with the joint venture agreement, we and Nordic entered into a registration rights agreement, on February 25, 2008, as modified pursuant to a letter agreement, dated September 17, 2008, pursuant to which we agreed to file with the Securities and Exchange Commission, or the SEC, by no later than 10 calendar days following the date on which our Annual Report on Form 10-K for the year ended December 31, 2007 is required to be filed with the SEC, which was subsequently waived by Nordic until May 1, 2008, an initial registration statement registering the resale by Nordic of any shares of our common stock issuable to Nordic through the exercise of the warrant or the put right. We filed an initial registration statement on May 1, 2008, which was declared effective on October 15, 2008.

We also have agreed to file with the SEC any additional registration statements which may be required no later than 45 days after the date we first know such additional registration statement is required; provided, however, that (i) in the case of the classification by the FDA of Hedrin as a Class II or Class III medical device described above and the payment in full by Nordic of the related final milestone payment of \$1.25 million, the registration statement with respect to the additional shares of our common stock relating to such additional investment must be filed within 45 days after achievement of such classification; and (ii) in the event we provide Nordic with notice of exercise of our right to call all or a portion of Nordic's equity interest in the Hedrin JV, a registration statement with respect to the shares of our common stock payable to Nordic in connection with such call right (after giving effect to any reduction in the number of such shares resulting from Nordic's refusal of all or a portion of such call in accordance with the terms of our joint venture agreement) must be filed within 16 days after delivery of such notice to Nordic. If we fail to file a registration statement on time or if a registration statement is not declared effective by the SEC within 105 days of the required filing date, or otherwise fail to diligently pursue registration with the SEC in accordance with the terms of the registration rights agreement, we will be required to pay as partial liquidated damages and not as a penalty, to Nordic or its assigns, an amount equal to 0.5% of the amount invested in the Hedrin JV by Nordic pursuant to the joint venture agreement per month until the registration rights agreement is declared effective by the SEC; provided, however, that in no event shall the aggregate amount payable by us exceed 9% of the amount invested in the Hedrin JV by Nordic under the joint venture agreement.

The Company was required to file an additional registration statement with 45 days of Nordic's investment of an additional \$1.25 million in the Hedrin JV in February 2009. The Company did not meet this requirement as it had our registration statements pending. The Company has requested a waiver until May 31, 2009 of Nordic's registration rights in order to meet this obligation. Nordic has verbally agreed to the waiver.

As per the Limited Partnership Agreement between the Company and Nordic (the "LPA") in the event that a limited partner in the Hedrin JV (a "Limited Partner") determines, in its reasonable good faith discretion, that the Hedrin JV requires additional capital for the proper conduct of its business that Limited Partner shall provide each Limited Partner with a written request for contribution of such Limited Partner's proportionate share, in accordance to the then respective equity ownership in the Hedrin JV, of such requested additional capital amount.

As per the terms of the LPA, if a Limited Partner declines to so contribute, elects to contribute but thereafter fails to do so timely, or elects to contribute and timely does contribute some, but not all of, its proportionate share of the requested additional capital amount, the other Limited Partner shall have the option to contribute the remaining balance of such requested additional capital amount.

As per the terms of the LPA, the General Partner shall determine the fair market value of the shares for purposes of determining how to allocate the number of shares of the Hedrin JV to be issued in consideration for the contribution of capital. If the General Partner is unable to determine the fair market value of the shares, the fair market value for the shares shall be determined in good faith by the contributing Limited Partner if such amount is equal to or greater than the most recent valuation of such Hedrin JV shares.

On December 31, 2009, Nordic Biotech Venture Fund II ("Nordic") delivered a written notice to the Company for a \$1,000,000 capital increase to the Hedrin JV. In January 2010, Nordic made its capital contribution to the Hedrin JV of \$500,000. The Company did not have sufficient funds to make such a capital contribution within the required time prescribed in the LPA.

The General Partner was unable to determine the fair market value of the shares. The contributing Limited Partner, Nordic, determined in good faith that the fair market value of the shares is equal to the most recent valuation. The most recent valuation was the February 2009 investment of \$1,500,000 into the Hedrin JV by Nordic at \$5,000 per share. As a result of Nordic's investing an additional \$500,000 in the Hedrin JV, the ownership percentages of the Hedrin JV have changed from 50% to Nordic and 50% for the Company to 52.38% to Nordic and 47.62% for the Company and the minimum return each year from the Hedrin JV that Nordic is entitled to receive increased from 6% to 6.34% on Hedrin sales.

In July 2010, Nordic delivered a written notice to us for a \$500,000 capital increase to the Hedrin JV and made a \$500,000 capital contribution. We do not intend to make a capital contribution to the Hedrin JV at this time. No valuation has been set yet for this capital contribution. Our ownership interest will be reduced once the valuation for this capital contribution has been set.

In a letter dated October 19, 2010, addressed to the Hedrin JV, Thornton & Ross (which licenses certain intellectual property with respect to the Hedrin product to the Hedrin JV) made a demand for assurances and alleged that the Hedrin JV has not used commercially reasonable efforts to develop and secure marketing authorization for the Hedrin product and that the Hedrin JV does not have the financial means to perform even the most basic obligations under the License Agreement between Thornton & Ross and the Hedrin JV. The assurances that Thornton & Ross demand are: (1) a realistic and comprehensive clinical development plan through FDA approval of the Hedrin product, (2) an aggressive, yet realistic, development plan and timetable through Hedrin product launch, (3) enforceable funding commitments from a liquid source initially of up to \$5 million, and (4) new management.

To our knowledge, the Hedrin JV has not yet formally responded to Thornton & Ross, and we expect that when the Hedrin JV does respond, the Hedrin JV will deny the allegations of not using commercially reasonable efforts to develop and secure marketing authorization for the Hedrin product. Our knowledge of the Hedrin JV's efforts to develop and secure marketing authorization for the Hedrin product, however, is limited from and after August 18, 2010, as we have been denied our right to actively participate in the Hedrin JV from and after that date. (This is part



of the disputes with Nordic that we are currently trying to resolve.) We believe that subsequent to August 18, 2010, representatives of Nordic and Thornton & Ross met, although no minutes of that meeting have been provided to us.

As to the list of four assurances that Thornton & Ross has demanded, based on the information that we have about the efforts of the Hedrin JV prior to August 18, 2010, we do not believe that Thornton & Ross is contractually entitled to such assurances. Notwithstanding our disputes with Nordic, we expect to work with Nordic to cause the Hedrin JV to respond to the Thornton & Ross letter within 30 days of its receipt by the Hedrin JV.

#### Disagreement with Nordic

In April 2010 Nordic filed a Schedule 13D/A (the "Amended 13D") with the SEC. We are not in agreement with the Amended 13D and have written a letter to Nordic explaining its disagreements. The Amended 13D shows an aggregate number of shares of the Company's common stock beneficially owned by Nordic of 216,666,666, or 65.5%. We believe the correct beneficial ownership is 85,714,286 shares, or 42.9%. The Amended 13D/A states that Nordic does not believe the Company's determination of the anti-dilution shares accruing to Nordic as a result of the 2010 Equity Financing was neither reasonable nor made in good faith. As we have previously stated we believe our determination was both reasonable and made in good faith. The Amended 13D/A further states that Nordic acquired the right to purchase an additional 5,555,556 shares of the Company's common stock upon exercise of the Nordic Put as a result of Nordic's making an additional investment in the Hedrin JV of \$500,000 in January 2010. We are not in agreement with this claim, there is no adjustment to Nordic's Put as a result of Nordic making additional capital contributions to the Hedrin JV. In the letter to Nordic the Company also points out that Nordic's valuation suggestions for the warrants issued in the 2010 Equity Financing ignore the concept of relative value inherent in the Hedrin JV Agreement.

#### 2010 Equity Financing

On March and April 2010, we raised aggregate gross proceeds of approximately \$2.6 million pursuant to a private placement of our securities (the "2010 Equity Financing"). We sold an aggregate of 104.3 Units for a purchase price of \$25,000 per Unit. We issued to each Investor units (the "Units") consisting of 357,143 shares of common stock, \$0.001 par value per share of the Company and 535,714 warrants, each of which will entitle the holder to purchase one additional share of Common Stock for a period of five years at an exercise price of \$0.08 per share. In addition in April 2010, the holder of the 12% Convertible Note with a stated value of \$400,000 and \$22,000 of accrued interest, exercised its option to convert its Debenture (including all accrued interest thereon) into 16.88 Units. The conversion price was equal to the per Unit purchase price paid by the Investors in the private placement.

#### Convertible 12% Note Payable

In October 2009, we sold a 12% Original Issue Discount Senior Subordinated Convertible Debenture with a stated value of \$400,000 and a warrant to purchase 2,222,222 shares of the Company's common stock, par value \$.001 per share for a purchase price of \$200,000. The Convertible 12% Note is convertible into shares of Common Stock at an initial conversion price of \$0.09 per share, subject to adjustment, or, in the event the Company issues new securities in connection with a financing, the Convertible 12% Note may be converted into such new securities at a conversion price equal to the purchase price paid by the purchasers of such new securities. The Convertible 12% Note was converted into the 2010 Equity Financing in April 2010 as described above.

#### Secured 12% Notes Payable

On February 3, 2009, we completed a private placement of 345 units, with each unit consisting of Secured 12% Notes in the principal amount of \$5,000 and a warrant to purchase up to 166,667 shares of our common stock at an exercise price of \$.09 per share which expires on December 31, 2013, for aggregate gross proceeds of \$1,725,000. The private placement was completed in three closings which occurred on November 19, 2008 with respect to 207 units, December 23, 2008 with respect to 56 units and February 3, 2009 with respect to 82 units.

To secure our obligations under the notes, we entered into a security agreement and a default agreement with the investors. The security agreement provides that the notes will be secured by a pledge of our assets other than (i) our interest in the Hedrin joint venture, including, without limitation, our interest in H Pharmaceuticals K/S and H Pharmaceuticals General Partner ApS, (ii) our rent deposit for our former office space, (iii) our refund of a prepayment and (iv) our tax refund for the 2007 fiscal year from the State of New York and City of New York. In

addition, to provide additional security for our obligations under the notes, we entered into a default agreement, which provides that upon an event of default under the notes, we shall, at the request of the holders of the notes, use our reasonable commercial efforts to either (i) sell a part or all of our interests in the Hedrin JV or (ii) transfer all or part of our interest in the Hedrin JV to the holders of the notes, as necessary, in order to fulfill our obligations under the notes, to the extent required and to the extent permitted by the applicable Hedrin JV agreements.

In connection with the private placement, we, the placement agent and the investors entered into a registration rights agreement. Pursuant to the registration rights agreement, we agreed to file a registration statement to register the resale of the shares of our common stock issuable upon exercise of the warrants issued to the investors in the private placement, within 20 days of the final closing date and to cause the registration statement to be declared effective within 90 days (or 120 days upon full review by the SEC). During the three month period ended March 31, 2009, we filed the registration statement, received a comment letter from the SEC, responded to the SEC comment letter and re-filed the registration statement. The registration statement was declared effective by the SEC on April 17, 2009.

## Commitments

### Development Commitments

At present the Company has no development commitments.

### Research and Development Projects

#### AST-726

AST-726 is a nasally-delivered form of hydroxocobalamin, a natural Vitamin B12, for the treatment of Vitamin B12 deficiency. We acquired global rights to AST-726 as part of the Ariston acquisition. AST-726 has demonstrated pharmacokinetic equivalence to intramuscular hydroxocobalamin, a marketed injection product for Vitamin B12 remediation. We believe that AST-726 may enable both a single, once-monthly treatment for maintenance of normal Vitamin B12 levels in deficient patients, and more frequent administration to restore normal levels in newly diagnosed B12 deficiency. Further, we believe that AST-726 could offer a convenient, painless, safe and cost-effective treatment for Vitamin B12 deficiency, without the need for intramuscular injections.

We have positioned AST-726 to currently require only a single, relatively small Phase III clinical trial prior to submission of a 505(b)(2) new drug application (“NDA”) to the FDA. In August 2010, we met with the FDA for the purpose of obtaining a Special Protocol Assessment (SPA) for the planned Phase III pivotal study. An SPA is an agreement with the FDA that the proposed trial protocol design, clinical endpoints, and analysis are acceptable to support regulatory approval. We expect to file the SPA with the FDA in the fourth quarter 2010.

We have developed a CMC/manufacturing process for AST-726 that we believe provides a commercially viable stability profile. We have two issued patents in the United States with respect to AST-726, one of which relates to its application in Vitamin B12 remediation.

More than 9 million people in the US are deficient in Vitamin B12, indicating substantial market potential for a facile, convenient, safe and effective treatment that can replace the need for painful and frequent intramuscular injections or other less than fully effective delivery forms. We believe that substantial market opportunity also exists internationally.

### Vitamin B12 Deficiency-Background of the Disease

Untreated Vitamin B12 deficiency can result in serious clinical problems including hematological disorders, such as life-threatening anemias, and a range of central and peripheral neurological abnormalities such as fatigue, confusion, cognition impairment, dementia, depression, peripheral neuropathies and gait disturbances. Neuronal damage may involve peripheral nerves, the spinal cord and the brain and if the condition is left untreated may become permanent. Furthermore, clinically asymptomatic patients with low normal or below normal Vitamin B12 levels may have changes in blood chemistries, including elevated levels of methylmalonic acid or homocysteine, known risk factors for

other medical conditions associated with an increased risk of circulatory problems, blood clots and cardiovascular disease.

A new study published in September 2010 in the journal Public Library of Science One, showed that high doses of B vitamins slow the rate of brain atrophy in patients with mild cognitive impairment. Brain atrophy, or brain shrinkage, is one of the main symptoms of mild cognitive impairment, a precursor to dementia, and sometimes Alzheimer's disease. The average brain atrophies, at a rate of 0.5% a year after the age of 60. The brains of those with mild cognitive impairment shrink by approximately 1% per year. Alzheimer's patients have brain shrinkage of 2.5% per year. The study results showed that high doses of B vitamins slows the rate of brain atrophy by approximately 30%. Also in September 2010, the World Alzheimer Report stated that global healthcare costs associated with dementia totaled \$604 billion, a sum greater than 1% of the global gross domestic product. These new data support our belief that there is strong economic incentive for care options that could prevent or slow the onset of dementia.

The primary diagnosis of Vitamin B12 deficiency is made when measurement of its blood concentration falls below the expected normal range of 200 to 900 picograms/ml. Vitamin B12 deficiency is most often caused by pathological conditions that limit the body's ability to absorb the vitamin from food. Such disorders include pernicious anemia, atrophic gastritis, problems caused by gastric surgical procedures to treat stomach cancer and obesity, Crohn's disease and simple age-related changes. Some studies show the inability to properly absorb Vitamin B12 as a side effect from chronic use of certain widely prescribed antacid medications such as Prilosec® and diabetes treatments such as Glucophage®.

Approximately 15% of the elderly and up to 40% of nursing home residents in the U.S. have Vitamin B12 deficiency. A study of over 11,000 U.S. civilians ages four and older found a 3% prevalence of Vitamin B12 deficiency in the general population using the 200 picograms/ml deficiency standard, indicating that approximately 9 million people in the U.S. are in need of B12 replacement therapy. Some experts advocate a higher deficiency standard of 300-350 picograms/ml on the basis that levels below this coincide with elevated methylmalonic acid and homocysteine, risk factors for cardiovascular disease as found in the Framingham Heart Study. On this basis the prevalence of Vitamin B12 deficiency increases substantially.

#### Current Treatments for Vitamin B12 Deficiency

Once Vitamin B12 deficiency is diagnosed by a simple blood test, the goal of treatment is generally to:

- o restore circulating blood levels to normal as rapidly as possible;
- o replenish and normalize the substantial stores of the vitamin in the body; and
- o institute a lifelong therapeutic regimen that will maintain normal levels of the vitamin.

We believe that parenteral (intramuscular injection) treatment is often considered the treatment of choice for Vitamin B12 deficiency. Cyanocobalamin is predominantly used for this purpose in the United States, but hydroxocobalamin, the active ingredient in AST-726, is also available for pediatrics and for adults for whom injection of cyanocobalamin is poorly tolerated. Hydroxocobalamin injection is the predominant treatment for Vitamin B12 deficiency in Europe.

In the United States, intramuscular injections are generally given by a physician or nurse, necessitating an office/medical center visit by the patient or a visiting nurse home call for each treatment. Following a diagnosis of B12 deficiency, injections are required quite frequently in order to restore normal vitamin levels. Once normalization is achieved, the frequency can be reduced to once or twice per month. While the treatment is usually highly effective, the inconvenience and cost of frequent office visits and the pain and side-effects associated with intramuscular injections are problematic for many patients.

Intranasal treatment with Vitamin B12 deficiency seeks to alleviate these problems, but the two intranasal products currently available in the United States have to be administered on a daily or weekly basis and are not recommended for the treatment of newly diagnosed patients. Both products are based on cyanocobalamin.

Oral or sublingual administration of high doses of Vitamin B12 can restore deficient patients to normal in certain cases. Such high dose supplements are generally available in pharmacies and nutrition/health food stores. Adequate results can almost certainly be obtained when nutritional insufficiency (e.g., strict vegan diet) is the primary cause of the problem. However, the normal gastrointestinal tract has a very limited capability to absorb Vitamin B12 and if this is compromised, as is the case in many deficient patients, oral or sublingual supplementation may not be ideal for rapidly restoring circulating levels and storage depots of the vitamin to normal. In such cases of pathological Vitamin B12 deficiency, intramuscular injection still often remains the current treatment of choice.

An unapproved Vitamin B12 patch is available in the United States, but we believe that its effectiveness in moderate to severe Vitamin B12 deficient patients is substantially untested.

#### Potential Advantages of Ariston's AST-726 Treatment

We believe that AST-726 treatment has the potential to directly substitute for and replace the need for injection treatment by applying the current injection frequency paradigms for both newly diagnosed and normalized Vitamin B12 deficient patients. AST-726 is proposed to be self-administered at home by the patient, without costly, time-consuming and inconvenient visits to a doctor's office or medical facility needed for each of the many intramuscular injections required for life. Because it is delivered through a nasal spray, additional advantages include freedom from injection pain and reduced anxiety in individuals, including children and the elderly, who may have fear of injections. We believe that the delivery profile of AST-726 is comparable to that of the marketed intramuscular injection, and that therefore newly diagnosed patients will be able to self-administer the nasal spray on a daily basis or several times a week to restore their Vitamin B12 status to normal and will then be self-maintained on a single monthly nasal spray treatment.

#### Additional Clinical Trial Is Needed

AST-726, a commercial nasal spray formulation of hydroxocobalamin, has satisfactorily completed preclinical toxicology, and an Investigational New Drug (“IND”) Application has been filed with the FDA. This product candidate is being developed utilizing the 505(b)(2) regulatory pathway. AST-726 has also successfully completed a safety and pharmacokinetic study in healthy volunteers and an end of Phase II meeting with FDA has been completed. We are planning a Phase III pivotal Vitamin B12 replacement study in the United States. The study is designed to enroll approximately 40 Vitamin B12 deficient patients currently treated with injection therapy. Patients will first be evaluated on injection therapy and then will receive AST-726 by nasal spray on a monthly basis for 12 weeks. The primary purpose of this study is to determine that levels of Vitamin B12 in the patients’ bloodstream remain within the normal range following monthly administration of AST-726. We anticipate that the data from this study and additional manufacturing information will support the planned 505(b)(2) new drug application (“NDA”) filing for AST-726. We currently do not have the financial resources to conduct the Phase III pivotal study. We estimate that the cost of such a study will be between \$1 million and \$2 million, it could be higher depending on the SPA agreement we reach with the FDA.

Through September 30, 2010 we have incurred \$297,000 of project costs related to the development of AST-726. These project costs have been incurred since March 8, 2010, the date of the Ariston merger.

#### Hedrin

Hedrin is a novel, non-insecticide, one hour treatment for pediculosis (head lice) that is currently being developed as a prescription medical device in the United States by H Pharmaceuticals, a joint venture entity between Manhattan Pharmaceuticals and Nordic Biotech. Hedrin is the top selling head lice treatment in Europe. It is currently marketed in over 30 countries and, according to Thornton & Ross Ltd. (“T&R”), achieved 2008 annual sales through its licensees of approximately \$48 million (USD) at in-market public prices, garnering approximately 23% market share across Europe.

Through September 30, 2010, Hedrin has been clinically studied in over 400 subjects. In a randomized, controlled, equivalence clinical study conducted in Europe by T&R, Hedrin was administered to 253 adult and child subjects with head louse infestation. The study results, published in the British Medical Journal in June 2005, demonstrated Hedrin’s equivalence when compared to the insecticide treatment, phenothrin, the most widely used pediculicide in the U.K. In addition, according to the same study, the Hedrin-treated subjects experienced significantly less irritation (2%) than those treated with phenothrin (9%).

An additional clinical study published in the November 2007 issue of PLoS One, an international, peer-reviewed journal published by the Public Library of Science (PLoS), demonstrated Hedrin’s superior efficacy compared to a U.K. formulation of malathion, a widely used insecticide treatment in both Europe and North America. In this randomized, controlled, assessor blinded, parallel group clinical trial, 73 adult and child subjects with head lice infestations were treated with Hedrin or malathion liquid. Using intent-to-treat analysis, Hedrin achieved a statistically significant cure rate of 70% compared to 33% with malathion liquid. Using the per-protocol analysis Hedrin achieved a highly statistically significant cure rate of 77% compared to 35% with malathion. In Europe it has been widely documented that head lice had become resistant to European formulations of malathion, and we believe this resistance had influenced these study results. To date, there have been no reports of resistance to U.S. formulations of malathion. Additionally, Hedrin treated subjects experienced no irritant reactions, and Hedrin showed clinical equivalence to malathion in its ability to inhibit egg hatching. Overall, investigators and study subjects rated Hedrin as less odorous, easier to apply, and easier to wash out, and 97% of Hedrin treated subjects stated they were significantly more inclined to use the product again versus 31% of those using malathion.



Two new, unpublished Hedrin studies were completed by T&R in 2008. In the first, Hedrin achieved a 100% kill rate in vitro, including in malathion resistant head lice. In the other, a clinical field study conducted in Manisa province, a rural area of Western Turkey, Hedrin was administered to 36 adult and child subjects with confirmed head lice infestations. Using per protocol analysis, Hedrin achieved a 97% cure rate. Using intent-to-treat analysis, Hedrin achieved a 92% cure rate since 2 subjects were eliminated due to protocol violations. No subjects reported any adverse events.

In April 2009, T&R published a clinical field study where 40 adult and child subjects with head lice infestations were treated with Hedrin using a 1 hour application time. Treatment was given twice with 7 days between applications. In this study, Hedrin achieved a cure rate of 90%.

In the U.S., the Hedrin JV is pursuing the development of Hedrin as a prescription medical device. In January 2009, the U.S. Food and Drug Administration (“FDA”) Center for Devices and Radiological Health (“CDRH”) notified H Pharmaceuticals that Hedrin had been classified as a Class III medical device. A Class III designation means that a Premarket Approval (“PMA”) Application will need to be obtained before Hedrin can be marketed in the U.S. In July 2009, CDRH confirmed that two pivotal studies, which can occur simultaneously, using the same protocol consisting of approximately 60 subjects each, or 120 subjects in total, are required for the completion of the PMA application. In April 2010, the Hedrin JV received correspondence from the FDA in which the FDA raised questions about certain manufacturing and non-clinical aspects of Hedrin (including certain deficiencies in safety documentation that will require further study). The Hedrin JV is in the process of responding to those questions and will not be able to commence the confirmatory clinical trials, and the Hedrin JV's application to conduct those clinical trials will not be accepted by the FDA, unless and until such questions are responded to, to the satisfaction of the FDA.

Through September 30, 2010 we have incurred \$1,084,000 of project costs for the development of Hedrin. None of these costs were incurred during the nine month period ended September 30, 2010. We do not expect to incur any future costs as the Hedrin JV is now responsible for all costs associated with Hedrin.

#### AST-915

AST-915 is an orally delivered treatment for essential tremor. AST-915 was formerly referred to as “AST-914 metabolite”. We acquired global rights to AST-915 as part of the Ariston acquisition. This product candidate is being studied under a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) and a Phase 1 clinical study is currently underway in essential tremor patients. We expect to announce results from this Phase I study in the fourth quarter of 2010.

Essential tremor is a neurological disorder that is characterized by involuntary shaking of the hands, arms, head, voice, and upper body. The most disabling tremors occur during voluntary movement, affecting common skills such as writing, eating and drinking. Essential tremor is often misdiagnosed as Parkinson’s disease, yet according to the National Institutes of Neurological Disorders and Stroke, approximately 8 times as many people have essential tremor as have Parkinson’s. Essential tremor is not confined to the elderly. Children, newborns, and middle-aged people can also have the condition.

Essential tremor is the most common involuntary movement disorder, with increasing incidence as people age. According to the National Institute of Health (NIH), essential tremor affects 14% of people 65 years and older, which equates to approximately 5.4 million Americans. There is no cure for essential tremor and the currently available drug therapies do not work in many patients, produce at best a 50% response in others, and have significant side effects. We believe AST-915 may provide a new treatment option for this serious and prevalent disorder. We believe that substantial market opportunity also exists internationally.

#### Topical GEL for Psoriasis

The gel vehicle (placebo) used in the below mentioned study is our proprietary topical GEL which unexpectedly showed evidence of psoriasis improving properties. At the end of week 2, 15% of study subjects treated with the GEL achieved a clear or almost clear state. At the end of week 4, 20% of subjects treated with the GEL had achieved a clear or almost clear state, and at the end of week 8, 25% of subjects had achieved a clear or almost clear state. We own worldwide rights to this topical GEL and are exploring the possibility of developing it as an OTC product for mild psoriasis.

In July 2008, we announced the results of a Phase 2a clinical study where Topical PTH (1-34) failed to show statistically or clinically meaningful improvements in psoriasis as compared to the vehicle (placebo). We have

conducted no further clinical activities with Topical PTH (1-34), terminated the agreement with IGI in May 2009 and have no further financial liability or commitment to IGI under the license agreement.

## Summary of Contractual Commitments

### Employment Agreement

None.

### Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements.

### Critical Accounting Policies

In December 2001, the SEC requested that all registrants discuss their most “critical accounting policies” in management’s discussion and analysis of financial condition and results of operations. The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of the company’s financial condition and results and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.

### Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

### Research and Development Expenses

All research and development costs are expensed as incurred and include costs of consultants who conduct research and development on behalf of the Company and its subsidiaries. Costs related to the acquisition of technology rights and patents for which development work is still in process are expensed as incurred and considered a component of research and development costs.

The Company often contracts with third parties to facilitate, coordinate and perform agreed upon research and development of a new drug. To ensure that research and development costs are expensed as incurred, the Company records monthly accruals for clinical trials and preclinical testing costs based on the work performed under the contracts.

These contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain milestones. This method of payment often does not match the related expense recognition resulting in either a prepayment, when the amounts paid are greater than the related research and development costs expensed, or an accrued liability, when the amounts paid are less than the related research and development costs expensed.

### Share-Based Compensation

We have stockholder-approved stock incentive plans for employees, directors, officers and consultants. Prior to January 1, 2006, we accounted for the employee, director and officer plans using the intrinsic value method. Effective January 1, 2006, we adopted the share-based payment method for employee options using the modified prospective transition method. This new method of accounting for stock options eliminated the option to use the intrinsic value

method and required us to expense the fair value of all employee options over the vesting period. Under the modified prospective transition method, we recognized compensation cost which includes a) period compensation cost related to share-based payments granted prior to, but not yet vested, as of January 1, 2006, based on the grant date fair value estimated in accordance with the original provisions; and b) period compensation cost related to share-based payments granted on or after January 1, 2006, based on the grant date fair value estimated in accordance with the new accounting methodology. In accordance with the modified prospective method, we have not restated prior period results.

### Item 3. Quantitative and Qualitative Disclosure About Market Risk

Our exposure to market risk is confined to our cash and cash equivalents. We have attempted to minimize risk by investing in high-quality financial instruments, primarily money market funds with no security having an effective duration longer than 90 days. If the market interest rate decreases by 100 basis points or 1%, the fair value of our cash and cash equivalents portfolio would have minimal to no impact on the carrying value of our portfolio. We did not hold any derivative instruments as of September 30, 2010, and we have never held such instruments in the past.

### Item 4. Controls and Procedures

#### Evaluation of Disclosure Controls and Procedures

As of September 30, 2010, we carried out an evaluation, under the supervision and with the participation of our Principal Executive Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")). Based upon that evaluation, our Chief Operating and Financial Officer concluded that our disclosure controls and procedures were effective as of that date to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and to ensure that information required to be disclosed by us in such reports is accumulated and communicated to our management, including our Chief Operating and Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Our disclosure controls or internal controls over financial reporting were designed to provide only reasonable assurance that such disclosure controls or internal control over financial reporting will prevent all errors or all instances of fraud, even as the same are improved to address any deficiencies. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be only reasonable, not absolute assurance that any design will succeed in achieving its stated goals under all potential future conditions. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.

Because of the inherent limitation of a cost-effective control system, misstatements due to error or fraud may occur and not be detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls.

#### Changes in Internal Control

During the quarter ended September 30, 2010, there were no changes in internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

Part II – Other Information

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

We are controlled by current officers, directors and principal stockholders; a dispute with our Hedrin JV joint venture partner may adversely affect the Company.

Our directors, executive officers and principal stockholders beneficially own approximately 20 percent of our outstanding voting stock and, including shares underlying outstanding options and warrants. In addition, Nordic Biotech Venture Fund has the right to acquire up to 85,714,285 shares of our common stock which would result in Nordic owning approximately 43% of our common stock as of September 30, 2010 (although, as described in Note 18 to our financial statements at and for the Years ended December 31, 2009 and 2008, and as described in an amendment to Nordic's 13-D filing with respect to the Company, an anti-dilution calculation with respect to this amount has been disputed by Nordic; Nordic alleges that using an alternative approach to valuing the Company's recent private placement of stock and warrants, an approach that the Company believes is neither correct nor appropriate, as a result of the anti-dilution adjustment Nordic would beneficially own 85,714,286 shares of our common stock, which represents 42.9% of our common stock as of September 30, 2010). Through its stock ownership, its right to acquire additional shares, its substantial control over the management of the Hedrin JV (which includes the ability to terminate our management contract with the Hedrin JV), Nordic has the ability to exert substantial influence over the election of our Board of Directors, the outcome of issues submitted to our stockholders, the development of Hedrin and our ability, as a company, to benefit from the successful development of Hedrin. Even without the exercise of its rights to acquire additional shares of our common stock, our directors, officers and principal stockholders, taken as a whole, have the ability to exert substantial influence over the election of our Board of Directors and the outcome of issues submitted to our stockholders. Any dispute with Nordic, including the dispute concerning the appropriate valuation methodology for the antidilution calculation, may adversely affect the Company's operations and the Company's ability to raise additional capital in the future, and may divert the Company's limited management time and attention,

Item 6. Exhibits

Exhibit No. Description

- |      |  |
|------|--|
| 31.1 | Certification of Principal Executive and Financial Officer   |
| 32.1 | Certifications of Principal Executive and Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |

SIGNATURES

In accordance with the requirements of the Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MANHATTAN PHARMACEUTICALS, INC.

Date: November 15, 2010

By: /s/ Michael G. McGuinness  
Michael G. McGuinness  
Principal Executive Officer



Index to Exhibits Filed with this Report

Exhibit No. Description

31.1 Certification of Principal Executive and Financial Officer.

32.1 Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

42

---